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Severe bacterial infections and sepsis are a major global cause of mortality 
and morbidity and with the number of antibiotic resistance cases on the rise. 
Despite the introduction of treatment guidelines such as those implemented 
by the surviving sepsis campaign mortality remains high and new therapies 
are desperately needed. One new therapy, which may be of benefit, is P4 
therapy – the combination of the immunomodulating peptide P4 and 
intravenous immunoglobulin (IVIG). The ability of P4 to augment 
phagocytosis in models of pneumococcal infections, decreasing bacterial 
burden and improving survival has previously been shown. This thesis goes 
on to investigate the efficacy of P4 therapy in models of Gram-negative 
infections, with and without antibiotics and in ex vivo studies from patients 
with severe community acquired pneumonia (CAP).  
Methods:  
Murine models of Escherichia coli and Klebsiella pneumoniae infection were 
used to evaluate the efficacy of P4 peptide with IVIG in the treatment of 
severe Gram-negative infections. Flow cytometry and ELISA were used to 
assessed immune responses to infection with P4 treatment.  
Neutrophils from patients with severe CAP were isolated and their responses 
to P4 assessed with ex vivo phagocytosis assays and flow cytometry. In vivo 
and ex vivo studies were performed with naïve mice and tissue culture cell 
lines to evaluate the effect of P4 on neutrophil receptor expression and the 
binding of P4 peptide to cells. 
Results: 
Treatment with P4 and IVIG in combination with antibiotics led to significant 
improvements in survival and bacterial burden in Klebsiella pneumoniae 
infection. Treatment of Escherichia.coli infection with P4 and IVIG in 
combination with antibiotics showed no benefits over treatment with antibiotic 
with IVIG, this was likely due to the infection being too severe.  
In neutrophils from CAP patients increases in bacterial killing when treated 
with P4 in phagocytosis assays were seen in 60% of patient. Patients who 
did not respond to the P4 treatment showed higher levels of IL-8 and IL-10 in 
their serum and higher disease severity scores.  
Conclusions:  
P4 treatment showed efficacy in the treatment of Klebsiella infection but data 
from E. coli infections and ex vivo treatment of CAP patient neutrophils 
suggest that infection severity and levels of IL-8 and IL-10 may effect 
treatment success. P4 could be a potential new treatment option for patients 
with severe bacterial infections but further studies are needed to better 
establish which patients would benefit from this treatment and the influence 
of host immune status on treatment efficacy.   
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The word sepsis dates back over 2000 years to ancient Greece, when 
Hippocrates defined sepsis, σήψις, as a process similar to putrefaction, the 
festering of wounds (1). Since that date sepsis has varied in meaning as 
understanding of the condition has developed, arriving at its current clinical 
definition as: a life-threatening organ dysfunction caused by a dysregulated 
host response to infection and septic shock defined as sepsis with persisting 
hypotension despite adequate volume resuscitation (2). 
1. Disease burden  
 
Sepsis presents a significant burden on healthcare systems; global annual 
cases are documented at 1.8 million although due to low rates of recognition 
this is likely an underestimate (3). In England alone there were 122,822 
cases between 2013 and 2014 and the number of cases is rising at a rate of 
around 10% year on year, this is likely due to people living longer with more 
chronic illnesses (4). Case-fatality rates for sepsis vary depending on 
severity: sepsis has a mortality of 30%, whereas severe sepsis and septic 
shock have mortality rates of 50 and 80% respectively (5). Mortality and 
incidence of sepsis also vary greatly with age; below 40 years in hospital 
mortality is between less than 5% and 15% whereas in those above 40 years 
there is a linear relationship between age and mortality. Incidence is highest 
in those under five years, is low between five and 40 years and then 
increases with age (6). Severe infections can progress into sepsis due to 
factors such as treatment failure and patient immune status; the most 
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common source of infection in sepsis is the respiratory tract followed by the 
genitourinary and gastrointestinal tracts (7). 
 Figure 1. Incidence of sepsis according to source of infection, stratified by 
sex. From Moss et al. 2005  (7) 
2. Diagnosis 
Until this year (2016) sepsis diagnosis followed fairly rigid criteria: evidence 
of suspected infection and 2 or more SIRS criteria: 
 Temperature >38°C or <36°C 
 Heart rate >90/min 
 Respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa) 
 White blood cell count >12 000/mm3 or <4000/mm3 or >10% immature 
bands  
This definition, which focused in on excess inflammation was deemed to be 
unhelpful in diagnosis as it had poor discriminant and concurrent validity 
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when identifying potential sepsis patients and fails to take into account the 
role of anti-inflammatory processes in disease progression (2).  
The new guidelines for the identifying of sepsis patients (workflow detailed in 
figure 2) are intended to ease early diagnosis of a condition which is protean 
in nature and in which a myriad of clinical signs and symptoms can be used 
for identification, many of which can be influenced by both pathogen and host 
heterogeneity. The quick SOFA (qSOFA) score was introduced to help 













































3. Costs of sepsis  
Sepsis is associated with high costs, both to healthcare systems and to the 
patients themselves. Sepsis patients account for almost one third of ICU 
admissions in the UK and almost half of these patients die in hospital (8). 
The cost of a single day in ICU in a European hospital ranges from €1168 - 
€2025 with ICU departments estimated to consume 20% of the total hospital 
budget (9). Figure 3 shows the breakdown of these direct costs, with the 
biggest expensive being staffing. 
Figure 3 Direct costs of sepsis in German ICUs 
Direct costs in German intensive care units (ICUs). Medication = drugs, fluids, 
nutrition. Invasive procedures includes diagnostic procedures, renal replacement 
therapy, and mechanical ventilation. Adapted from (10). 
 
With sepsis patients making up such a high proportion of ICU patients they 
present a significant financial burden and are estimated to cost the NHS £2 
billion a year. Direct cost of treatment per case of severe sepsis range from 
€23,000 to €29,000 in Europe and €34,000 in the US; this cost only 
represents 20-30 % of the total cost with 70-80 % of costs being indirect, 
mainly due to productivity losses (11).        
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As well as high fiscal costs patients can also suffer from long term sequela 
such as cognitive and physical impairments, muscle weakness, wasting and 
fatigue as well as the worsening of existing chronic conditions (12-14). 
Sepsis patients are 1.5 times more likely to be readmitted to hospital within 
30 days of discharge than non-sepsis patients and are also more likely to die 
or move into hospice care (15).     
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B. Gram negative infections 
Although Gram-positive infections are the most common cause of sepsis, 
having superseded Gram-negative infections as the leading cause in the 
mid-late 1980s, Gram-negative infections still constitute a high proportion of 
cases (16). Gram-negative infections account for only 38% of reported cases 
sepsis (Gram-positive cases constitute 52% of cases, while fungal infections 
constitute 10%) but they are highly prevalent as bloodstream infections and 
infections with Escherichia coli and Klebsiella spp. are on the rise (17). 
Figure 4 Blood infection-causing organisms  
In adults England, Wales and Northern Ireland April 2011 – May 2012. Source: 
Department of Health 
 
1. Escherichia coli 
E. coli is an extremely versatile microorganism and is the most prevalent 
commensal in the gut of humans and warm-blooded animals. As well as 
being a harmless commensal, E. coli also exists as a number of pathotypes 
capable of causing disease in health humans. Of these pathotypes (listed in 
Table 1) the extra-intestinal E.coli: uropathogenic (UPEC) and neonatal 
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meningitis (NMEC) are of particular interest as the causative agents of 
urosepsis and neonatal meningitis and sepsis.  
a) Urosepsis  
Urinary tract infections (UTI) are extremely common with approximately 150 
million cases globally per year and they are the second most common 
reason for antibiotic prescription (19). In elderly patients, diabetics and 
immunosuppressed patients there is a higher risk of UTIs developing into 
urosepsis, this risk is multiplied further by hospitalisation where interventions 
Table 1 E. coli pathotypes 
Pathotype (acronym) Diseases 
Enteric E.coli 
EnteroPathogenic E. coli (EPEC) Diarrhoea in children 
EnteroHaemorrhagic E. coli(EHEC) Haemorrhagic colitis, haemolytic-uremic syndrome 
EnteroToxigenic E. coli (ETEC) Traveller’s diarrhoea 
EnteroAggregative E. coli (EAEC) Diarrhoea in children 
Diffusely Adherent E. coli(DAEC) Acute diarrhoea in children 
EnteroInvasive E. coli (EIEC) Shigellosis-like 
Adherent Invasive E. coli (AIEC) Associated with Crohn disease 
Extraintestinal E. coli (ExPEC) 
UroPathogenic E. coli (UPEC) Lower UTI and systemic infections 
Neonatal Meningitis E. coli (NMEC) Neonatal meningitis 
Avian Pathogenic E. coli (APEC) Probable source of food-borne disease 
From Allocati et al. 2013 (18)  
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such as the placement of indwelling urethral catheter, ureteric stents and 
nephrostomy tubes further increase risk (20). Catheter-associated UTIs 
account for 40% of hospital acquired infections (19). E. coli is the most 
common cause of UTI and UPEC isolates account for 75-95% of total cases 
and 65% of hospital acquired UTIs (Klebsiella spp, Pseudomonas 
aeruginosa and Proteus spp have higher incidence in a hospital setting than 
the community) (21). Urosepsis constitutes 5% of sepsis cases overall with E. 
coli the causative agent in 50% of these cases (21). Urosepsis is becoming 
an increasing public health issues with the aging population and increases in 
antibiotic resistance, which is highly prevalent in UPEC strains due to their 
propensity to cause occult chronic infections.    
b) Neonatal sepsis and meningitis 
Infection remains a major cause of mortality in neonates with 7% of all 
deaths in children under five year old caused by neonatal sepsis (Figure 5). 
Neonatal sepsis can be divided into two groups: early-onset sepsis (EOS), 
within one week of birth (some studies state 72 hours) and late-onset sepsis 
(LOS), after one week from birth. EOS is thought to be due to maternal 
intrapartum transmission of infectious organisms whilst LOS is thought to be 
due to postnatal infection with preterm infants being particularly at risk as a 
result of prolonged hospitalization and use of indwelling catheters, 




Figure 5. Cause of death in children under 5 years, 2015 
Adapted from WHO 2016 (23) 
Neonatal sepsis due to E. coli has increased in recent years and is the most 
common cause of early on-set sepsis in very low birth weight neonates 
(VLBW); those weighing less than 1500 grams. E. coli is often associated 
with more severe infections and meningitis and it has become the principal 
cause of sepsis-related mortality among VLBW infants (24.5%) and the 
second most common cause in infants at term (22). 
Premature births are more susceptible to infection due to their immature 
immune systems; compared with adults, neonate cells have lower pro-
inflammatory cytokine production, lower expression of neutrophil adhesion 
molecules, decreased response to chemoattractants and increased induction 
of IL-10 (24-26). The majority of transplacental passage of IgG occurs in the 
later stages of pregnancy with IgG concentrations only reaching 50% 
between weeks 28-32 of gestation, which means premature births have a 
reduced level of humoral immunity compared with term births (27). 
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Complement levels increase with age but are still significantly lower than 
adult levels at term, with a marked deficiency in the levels of C9 limiting the 
formation of the membrane attack complex (28).  
Neonatal meningitis is primarily caused by E. coli isolates belonging to the 
NMEC pathotype, the condition has a high mortality rate of between 15 and 
40% and is associated with severe long term neurological defects in 
survivors (29). Bacteraemia is a prerequisite to meningeal infection with the 
infection being spread haematogenously; 80% of NMEC isolates possess a 
K1 capsule, which although not necessary for traversing the blood-brain 
barrier is essential for survival (29, 30). Invasion of the blood-brain barrier by 
E. coli is a function of bacterial burden with the risk of invasion increasing 
with bacterial counts of more than 103 per ml of blood (31). 
Treatment of neonatal infections are complicated as the drug dosing 
schedules and concentrations are based on the pharmacokinetics and 
pharmacodynamics data from adult trials. Intrapartum interventions for the 
prevention of Group B Streptococcus (GBS) infection (antibiotics for 
prophylaxis or suspected chorioamnionitis) have shown great benefits in 
reducing the incidence of EOS caused by GBS – no such intervention exists 
of E. coli and prevention remains a challenge (32). Improvements in the 
recognition of EOS are needed in order to help prevent the unnecessary 
treatment of neonates with antibiotics (33).   
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c) Peritonitis and intra-abdominal sepsis  
The term intra-abdominal infection covers an array of different etiologies (see 
Table 2) and abdominal infection is the third most common cause of sepsis 
after pulmonary and genitourinary infection (34).  
Table 2 Potential etiology of intra-abdominal infections (35) 
Gastrointestinal Anastomotic leak Iatrogenic perforations 
 Appendicitis Inflammatory bowel disease  
 Clostridium difficile colitis Meckel diverticulum 
 Diverticulitis Peptic ulcer disease 
 Fistula formation Perforated neoplasm 
 Gastrointestinal malignancy Perforating trauma 
 Biliary Acalculous cholecystitis Ascending cholangitis 
 Acute calculous cholecystitis Intrahepatic abscess 
Retroperitoneal Acute pancreatitis  
 Kidney abscess  
 Pyelonephritis  
Pelvic Endometritis Parametritis 
 Extrauterine pregnancy Pelvic inflammatory disease 
 Oophoritis Salpingitis 
 Ovarial abscess Tubal abscess 
Others Blunt trauma  Spontaneous bacterial peritonitis 
 Intrasplenic abscess   
Peritonitis can be categorised into primary, secondary or tertiary peritonitis. 
Primary peritonitis is defined as peritonitis with no obvious cause (such as 
breach of the GI tract), is usually monobacterial and its most frequent 
presentation is spontaneous bacterial peritonitis in patients with cirrhosis or 
ascites (35). Secondary peritonitis is caused by perforations of a hollow 
viscus due to inflammation or malignancy, less common causes include 
superinfection of ischemic necrosis, fistulas, trauma, or iatrogenic causes 
such as leakage from anastomotic sites (35). Tertiary peritonitis is defined as 
a persistent or recurrent peritoneal infection, usually the result of failed 
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treatment of a secondary peritonitis, 20% of secondary peritonitis patients 
progress to tertiary peritonitis and it is associated with a high incidence of 
nosocomial and multidrug resistant infections, high mortality, immune 
dysfunction and more severe organ dysfunction (35). Enterobacteriaceae are 
by far the most commonly isolated pathogens from peritoneal infections 
within which E. coli and K. pneumoniae predominate, although infections 
from secondary peritonitis are often polymicrobial (seeTable 3).  
Table 3 Aerobic bacteria identified from intra-operative peritoneal fluid (36) 
Total 1330 (100%) 
Aerobic Gram-negative bacteria 957 (71.9%) 
E. coli 548 (41.2%) 
(E. coli resistant to third generation cephalosporins) 75 (5.6%) 
K. pneuumoniae 140 (10.5%) 
(K. pneumoniae resistant to third generation cephalosporins) 26 (1.4%) 
K. oxytoca 11 (0.8%) 
(Klebsiella oxytoca resistant to third generation cephalosporins) 2 (0.1) 
Enterobacter 64 (4.8%) 
Proteus 47 (3.5%) 
Pseudomonas 74 (5.6%) 
Others 73 (5.6%) 
Aerobic Gram-positive bacteria 373 (29.1%) 
Enterococcus faecalis 153 (11.5%) 
Enterococcus faecium 58 (4.4%) 
Staphylococcus Aureus 38 (2.8%) 
Streptococcus spp. 85 (6,4%) 
Others 39 (2.9%) 





2. Klebsiella pneumoniae 
Klebsiella spp. are ubiquitous in the environment as well as being a common 
commensal in the human and animal gastrointestinal tract. K pneumoniae 
and K oxytoca are the two species responsible for most human infections.  
a) K. pneumoniae in community acquired pneumonia 
Although thought to be an important cause of community acquired 
pneumonia between the 1920s-1960s K. pneumoniae is now a relatively 
uncommon cause of CAP with incidence in the US estimated at less than 
1%. It should be noted however that diagnosis rates in CAP are low with 
failure to identify the etiological agent being as high as 65% (37, 38). In some 
regions (Taiwan and South Africa) and in specific patient groups (alcoholics 
and males with leukopenia) K. pneumoniae does still cause a significant 
proportion of CAP (39). These cases of primary CAP, caused by 
hypervirulent K. pneumoniae isolates (discussed further below) have higher 
mortality rates (55.1%) and marginally higher incidence (31%) than CAP 
caused by S. pneumoniae (mortality 27.3%) in these regions (39, 40). 
K. pneumoniae in western countries is however still an important cause of 
nosocomial infections accounting for around 10% of hospital-acquired and 
ventilator-acquired bacterial pneumonias as well as being a common cause 
of hospital-acquired UTI and is also commonly found in the lungs of chronic 
pulmonary obstructive disorder (COPD) patients (38, 39, 41).   
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b) Hypervirulent Klebsiella pneumoniae 
In addition to K. pneumoniae causing respiratory infections and UTIs, 
invasive liver abscess syndrome (defined as K. pneumoniae liver abscess 
with extrahepatic complications, particularly CNS involvement, necrotising 
fasciitis, or endophthalmitis) has become a significant problem, spreading out 
from Southeast Asia over the last 20 years and being increasingly identified 
in the west (42, 43). This infectious syndrome is of particular concern as it is 
caused by hypervirulent (also referred to as hypermucoviscous) isolates of K. 
pneumoniae capable of causing infection in healthy adults in the community 
and has mortality ranging from 3-42% despite infecting a relatively healthy 
group of patients compared with those infected with the “classical” K. 
pneumoniae isolates common in respiratory infections (44).  
The reason for the increased virulence of these isolates is not well defined 
although higher production of siderophores (resulting in improved iron 
acquisition) compared to “classical” isolates is thought to play an important 
role (45). The hypermucoviscous phenotype is also thought to be significant 
factor, with the trait being used to provisionally identify hypervirulent isolates 
via a “string test” (Figure 6). Whether this phenotype is a result of increased 
capsule production or due to the presence of extracapsular polysaccharide is 
contested, although it has been shown that the majority of hypervirulent 
isolates possess copies (both chromosomally and on plasmids) of both the 
rmpA and rmpA2 genes (positive regulators of capsule production). The 
presence of both these genes is uncommon in capsular serotypes not 
associated with hypervirulent isolates (46).     
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Figure 6 Positive “string test” on a hypervirulent strain of K. pneumoniae 
String test is deemed positive if the dipping of a loop into a culture can produce a 
viscous string of more than 5 mm (44). 
Hypervirulent K. pneumoniae isolates, in general, are more susceptible to 
antibiotics than their “classical” counterparts, with speculation that their 
higher levels of capsule expression make them less able to acquire plasmids 
or that antibiotic resistance genes have been lost in these isolates when they 
become hypervirulent (47). However, studies from China have shown 
resistance to antibiotics is increasing over time, with carbapenems being the 
only antibiotic some hypervirulent isolates show sensitivity to (47). With this 
in mind, hypervirulent K. pneumoniae has the potential to become the next 
“super-bug”.            
3. Antibiotic resistance 
Antibiotics have been in use for over 60 years and have long been 
considered the panacea for infectious disease and hence have been 
extensively misused in the treatment of both humans and in food-producing 
animals. In Alexander Fleming’s Nobel Prize speech in 1945, awarded for the 
discovery of penicillin, he warned of the development of antimicrobial 
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resistance and already by the 1950s penicillin resistant Staphylococcus 
aureus was common place in hospitals (48). Since that time antibiotic 
resistance has increased to the extent that bacteria commonly causing 
infections in hospitals and the community show resistance of 50% or more to 
commonly used antibiotics across the globe (Table 4).  
  
 
Table 4 Bacteria commonly causing infections in hospitals and communities 
From WHO Antimicrobial Resistance Global Report on Surveillance 2014 
 
Along with increasing antibiotic resistance there has been a paucity of new 
antibiotics coming into use, with no new antibiotic classes discovered since 
the late 1980s (Figure 7). The development of new antimicrobials is high cost 
and antimicrobials do not constitute a good investment for pharmaceutical 
companies as the public health policy to limit the usage of antibiotics in order 
to preserve their efficacy runs in direct opposition of traditional sales-based 





Figure 7 Dates of discovery of distinct classes of antibacterial drugs 
From Silver et al. 2011  (50) 
The evidence that antibiotic resistance exists in the environment and is hard 
wired into the microbial pangenome is increasing with studies from isolated 
environments such as the Lechugiilla caves in New Mexico showing 65% of 
Gram-negative isolates were already resistant to 3-4 commonly used 
antibiotics (51). With this in mind, development of resistance seems 
inevitable with the inappropriate use of antibiotics helping drive selection of 
genes mediating resistance.  
Antibiotic resistance is becoming an increasing issue for both E. coli and 
Klebsiella spp.  
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4. Antibiotic failure 
Inappropriate antibiotic treatment (i.e. where the pathogen shows no 
sensitivity in vitro to the prescribed agent) is a significant issue in the 
management of infection. Inappropriate antibiotic treatment is estimated to 
be between 15 % for community-acquired infections and reaching as high as 
35 % in nosocomial infections admitted to ICU (52). When initial empirical 
antimicrobial therapy fails in patients in septic shock there is an associated 
reduction in survival of approximately five-fold (55% to 11%); this rise in 
mortality risk applies to both Gram-positive, Gram-negative and Candida 
species (53). 
With the spread of antibiotic resistance treatment failure is likely to become a 
more frequent occurrence. Resistance to last line antibiotics such as colistin 
and tigecycline is emerging and infections for which there is no treatment 
option available are starting to occur, especially in E. coli and Klebsiella 
infections (54-56).  
The possibility of a “post-antibiotic era” speculated about in the media over 
the last few years might soon become a reality if new treatment options are 




C. Neutrophils and phagocytosis  
Elie Metchnikoff, holder of the epithet “the father of natural immunity”, who 
pioneered research in phagocytosis, first coined the term phagocyte in 1883: 
a fusion of the Greek word phago “eating” and the New Latin cyta which 
takes its origin from the ancient greek kútos meaning “vessel or jar”. 
Metchnikoff’s description of the role of phagocytes still holds true to this day: 
“The broad fact that the invasion of the organism by microbes most often 
induces, on the one hand, an inflammatory reaction with its associated 
emigration of leukocytes, and that, on the other hand, the phagocytes are 
capable of including and destroying the invaders, leads us to admit that the 
afflux of phagocytes to the invaded region and their bactericidal properties 
are mechanism which serve to ward off bacterial attack and to maintain the 
integrity of the organism” (57),.  
Neutrophils, a subclass of granulocytes, are professional phagocytes and the 
most abundant of all the leukocytes constituting 40 – 75 % of the circulating 
population of leukocytes in humans. Neutrophils, like all myeloid cells, derive 
from the bone marrow where neutrophil production constitutes the primary 
function (by volume) of the bone marrow, with basal rate estimated at 
5 × 1010–10 × 1010 neutrophils/day. Stages of maturation of neutrophils in 
bone marrow is summarised in Figure 8. Estimates of the half-life of 
neutrophils in the circulation vary significantly and can also be effected by 
disease state; estimates range from a few hours to over five days, although 
the study reporting a value of five days has received some criticism for its 
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techniques used, and a more conservative estimate sits at around six to eight 
hours (58, 59).  
Figure 8 Production of the neutrophil lineage in the bone marrow.  
Numbers in brackets represent total amount of each cell type per kg bodyweight. 
From Tak 2013 (58). 
 
1. Neutrophils during infection  
Neutrophils are a crucial component of the host immune defence; patients 
with a neutrophil count of less than 0.5 x 109 /L or defects in phagocytosis 
have an increased risk of recurrent and severe bacterial or fungal infections 
(often from uncommon pathogens) as well as poor wound healing, skin and 
deep visceral abscesses (60, 61).   
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a) Neutrophil recruitment 
The recruitment of neutrophils to the site of infection involves a cascade of 
events initiated by interactions between bacteria and host cells (62). The 
receptors that facilitate neutrophil infiltration are tissue specific; Figure 9 
details the process in the lower respiratory tract and how the actions of the 
neutrophil can be a double-edged sword, facilitating clearance of infection 
but also causing tissue damage to the host (62-64).  
Figure 9 Schematic describing the cascade of events by which bacteria 
induce neutrophil infiltration and tissue damage in the lung  
Bacteria first interact with epithelial cells and macrophages within the respiratory 
airway (1), this induces release of cytokines and neutrophil chemoattractants (2). 
Adhesion molecules on capillary endothelial cells are upregulated (3) and allow the 
transmigration of neutrophils into the alveolar spaces, following the chemotactic 
gradient (4). Neutrophils produce ROS and RNS (5), this can lead to necrotic cell 




A myriad of chemoattractants are capable of recruiting neutrophils to the site 
of infect, a list of these is detailed in Table 5. With such an array of 
chemoattractants showing the capacity to recruit neutrophils one may expect 
a degree of redundancy yet studies in inflammatory diseases have shown a 
temporal and spatial pattern of expression and an ability for neutrophils to 
prioritise chemotactic signals for efficient tissue homing; for example C5a, 
C3a and formylated peptides (which are found closer to the foci) are 
prioritised over IL-8 which is found more distally from sites of infection (65, 
66).  
Chemokines 
Systematic Human Murine Human Receptor Murine Receptor 
CXCL1 GROα KC CXCR2 CXCR2 
CXCL2 GROβ MIP-2 CXCR2 CXCR2 
CXCL3 GROγ n/a CXCR2 n/a 
CXCL5 ENA-78 LIX CXCR2 CXCR2 
CXCL6 GCP-2 n/a CXCR1/CXCR2 n/a 
CXCL7 NAP-2 NAP-2 CXCR1/CXCR2 CXCR2 
CXCL8 IL-8 n/a CXCR1/CXCR2 CXCR2 
CCL3 MIP-1α MIP-1α n/a CCR1 
CCL5 RANTES RANTES n/a CCR1 
CCL6 (MPIF-1) C10 n/a CCR1 
CCL7 MCP-3 MARC n/a CCR1 
CCL9 (HCC-2) MIP-1γ n/a CCR1 





Formylated peptides (e.g. fMLF) FPR1 





Leukotriene B4 (LTB4) BLT1 
Platelet activating factor (PAF) PAFR 
Table 5 Major human and murine neutrophil-active chemoattractants and their 
receptors expressed on neutrophils. Adapted from Sadik 2011 (65) 
Chemoattractants, along with microbial products, chemokines and 
inflammatory cytokines prime neutrophils, increasing phagocytosis efficiency 
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and ROS production in order to respond to infectious insults effectively (67). 
Priming of neutrophils increases expression of CD11b, CD35 FcγRs and 
CD66b, all thought to be released from intracellular stores via the exocytosis 
of secretory vesicles, without the need for de novo synthesis, allowing for 
rapid (10-15 min) responses to infection (68-72). Inflammatory cytokines also 
augment respiratory burst by phosphorylating NADPH oxidase components 
and deployment of flavocytochrome b558 from granules to plasma and 
phagosomal membranes (73-78). There is evidence from inflammatory 
conditions that a truly primed neutrophil also requires the expression of CD54 
dectin-2 and IL-1β promoter activation, which necessitates transcription of 
proteins and therefore is less rapid and takes several hours (67).  
b) Neutrophil – Bacterial killing  
Neutrophils utilise three methods for bacterial killing: phagocytosis, 
degranulation and the release of neutrophil extracellular traps (NETs).  
(1) Degranulation 
Degranulation involves the release of granules containing proteins capable of 
killing microbes and digesting tissue: these are azurophilic (primary) 
granules, which contain myeloperoxidase (MPO), specific (secondary) 
granules, which contain lactoferrin, and gelatinase and (tertiary) granules, 
which contain matrix metalloproteinase 9. The production of granules marks 
the transition from myeloblast to promyelocyte with different granules 
appearing throughout development; specific granules occurring during the 
myelocyte and metamyelocyte stages are followed by the appearance of 
gelatinase granules in band cells (79). Degranulation can be triggered by 
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stimuli such as exposure to microbial products, binding of immune 
complexes, exposure to TNF-α and is regulated by interactions with cellular 
adhesins (80-82).   
(2) Neutrophil extracellular traps 
Neutrophil extracellular traps (NETs) are extracellular strands of 
decondensed DNA in complex with histones and granule proteins released 
by neutrophils. Extracellular trap formation has also been shown in mast 
cells, eosinophils, basophils, fibrocytes, macrophages and monocytes (83-
88). This release of DNA, histones and granule proteins is effective in 
immobilising and killing some bacteria although it has been shown to be 
detrimental in other infections, for example the Pseudomonas aeruginosa 
exotoxin pyocyanin induces NETosis, which has been shown to play a role in 
the chronic inflammatory condition found in the cystic fibrosis lung (89) (90). 
NET formation has also been shown to have some protective effects during 
experimental systemic viral infections (91); whether NETosis is beneficial or 
not to the host depends on the anatomical site and infecting pathogen (90). 
Initially NETosis was considered to be a pathway of neutrophil cellular death, 
distinct from apoptosis and necrosis however a study in Staphylococcus 
aureus infection has now shown that NETosis can occur whilst the neutrophil 
maintains viability (92). NETosis has also been shown to be regulated by the 
size of the pathogen encountered; small pathogens such as bacteria induce 
phagocytosis whereas larger pathogens, which neutrophils would not be able 
to phagocytose, such as fungal hyphae or bacterial aggregates induce 
NETosis (93). Induction of either the phagocytosis or the NETosis pathway 
results in the inhibition of the other pathway (93). Excessive NETosis can 
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have a harmful effect during infection; the levels of cell free DNA (a surrogate 
marker for NET formation) correlates with sepsis severity and organ 
dysfunction as they contribute to tissue damage and histones can disrupt the 
function of some anticoagulants, which could effect the efficacy of 
prophylactic anticoagulants (94) (95). 
(3)  Phagocytosis 
The first step in phagocytosis is recognition of the target to be phagocytosed, 
phagocytes possess an array of receptors for this purpose listed in Table 6. 
Pattern-recognition receptors can bind directly to bacterial and fungal 
proteins and sugars whereas the opsonic receptors recognise an opsonin, 
which is in turn bound to the bacterial or fungal surface (96).  
Table 6 Human phagocytic receptors Adapted from Freeman et al 2014 (96) 
Opsonic receptors Pattern-recognition receptors 
FcγRI (CD64) Dectin-1 (CLEC7A)‡ 
FcγRIIA (CD32a) CD14 
FcγRIIC (CD32c) Mannose receptor 
FcγRIIIA (CD16a) BAI1 
FcαRI (CD89) CD36 
FcεRI MARCO 
CR1 Scavenger receptor A (CD204) 
CRIg  
CR3 (αMb2, CD11b/CD18, Mac-1) 
 




Opsonic and pattern-recognition receptors work in concert to facilitate 
phagocytosis. For successful phagocytosis remodelling of the cytoskeleton is 
required in order to engulf the particle in question; this is influenced by 
signalling from cell surface receptors where a signalling threshold must be 
met, otherwise stalling of phagocytosis can occur. This threshold has been 
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linked to the density of FcγR signalling in the early stages of phagocytic cup 
formation and 3′ phosphoinositide concentrations in later stages but is also 
influenced by properties of the target such as shape and rigidity (97-99).  
Figure 10 Phagosome formation and maturation  
i. Particle engagement, ii. Phagocytic cup formation and iii. Nascent phagosome 
After ligation of FcγRs the first detectabable signalling event occurs: rapid 
phosphorylation of tyrosine residues within an immunoreceptor tyrosine-based 
activation motif (ITAM) domain, these are located either in the cytoplasmic tail of the 
receptor (CD32A) or in the associated homodimeric g-subunit (other FcγR) (100). 
This phosphorylation is mediated by Src- family tyrosine kinases (101). FcγR 
phosphorylation also promotes clustering of FcγR, which improves the efficiency of 
phagocytosis (102). ITAM-domain tyrosine residues form docking sites for Src 
homology 2 (SH2) domain-containing proteins. Syk is of particular importance to 
ITAM-dependent phagocytosis (101). This leads to activation of Rho GTP-binding 
proteins. FcγR-dependent engulfment requires Cdc42 and Rac2 (Rho-family 
proteins), whereas CR3 requires RhoA (without the requirement of tyrosine 
phosphorylation), both require RhoG (103). Arp2/3 is recruited and binds directly 
with WASP (Wiskott-Aldrich Syndrome Protein) and Scar/WAVE (Suppressor of 
cAMP receptor/WASP family Verprolin-homologous) proteins which act as 
nucleation points for actin (104) In addition to actin recruitment the surface area of 
the phagocyte increases during phagosome formation through the recruitment of 
recycling endosomes, late endosomes, endoplasmic reticulum and secretory 
vesicles to the site of phagosome cup (104). The actin forms pseudopod extensions, 
which engulf the particle, followed by the shedding of cytoskeleton proteins leaving 
the phagosome free in the cytosol (105). 
iv. Early phagosome (2-10 min after sealing), v. late phagosome (10–30 min after 
sealing, vi. phagolysosome (>30 min after sealing).  
Adapted from Steinberg et al. 2008 (106) 
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After sealing of the phagosome there is sequential fusion of early (EE), late 
(LE) endosomes and lysosomes (LY) with each step marked by the 
recruitment of specific molecules and a decline in pH: 
Organelle Markers 
early endosome;  
early phagosome 
EEA-1, Rab5, PI(3)P, syntaxin-13, transferrin receptor, 
VAMP3 
pH 6.1 
Late endosome;  
late phagosome 
Rab7, Rab9, mannose-6-phosphate receptor, syntaxin-7, 
LAMPs, LBPA 
pH 5.5 –pH 6.0  
Lysosome;  
phagolysosome 
LAMPs, mature cathepsin D; fluid-phase markers chased 
for ≥2 hr 
pH 4.5 – pH 5.5 
Adapted from Scott et al. 2003 (107) 
This process results in phagoslysosome with a very low pH, hydrolytic 
enzymes for particle digestion, defensins and other bactericidal peptides, and 





(a)  Fc gamma receptors (FcγRs)  
FcγRs, so named, as these are the receptors that bind to the Fc portion of 
IgG, are key to opsonophagocytosis. FcγRs form the bridge between the 
innate and adaptive immune response, utilising IgG produced via an adaptive 
immune response to react to an infectious insult. In humans there are four 
FcγR types that participate in phagocytosis: FcγRI (CD64), FcγRIIA (CD32a), 
FcγRIIC (CD32c), FcγRIIIA (CD16a) (109). FcγRIIIB (CD16b) is another 
FcγR that does not directly contribute to opsonophagocytosis but is 
constitutively expressed by neutrophils and has a role in cell activation, Ca2+ 
release and cross-linking of this receptor has been shown to induce NETosis 
(110, 111). In mice, only FcγRI (CD64), FcγRIII (CD16) and FcγRIV have 
been identified; receptor affinities for IgG are show in Figure 11(109).  
 
Figure 11 Comparison of human and murine FcγRs  
FcγRs found on both humans and mice cells, their IgG binding affinity and whether 
binding of immune complexes results in activation or inhibition of cell function. 
Adapted from Schwab et al. 2013 (112) 
 
In addition to the receptors mentioned above, FcγRIIB (CD32b), an inhibitory 
receptor, belongs to this class. CD32b is not thought to be expressed on 
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human neutrophils with its expression limited to B cells; CD32b’s role being 
the negative regulation of antibody production (109). In mice, however, 
CD32b is expressed on neutrophils (109).  
(b) Antibodies 
Antibodies are a major component of humoral immunity and are one of the 
most abundant protein components of the blood, making up about 20% of the 
total protein in plasma by weight. Patients with primary antibody deficiencies 
are more susceptible to infection and are often treated with immunoglobulin 
replacement therapy with products such as intravenous immunoglobulin 
(IVIG) (113)   
In humans antibodies exist as 5 classes: IgA, IgD, IgE, IgG and IgM. IgG is 
important in opsonophagocytosis as it can interact with FcγRs (as well as 
glycan binding receptors DC-SIGN and CD23) and is capable of inducing 
antibody-dependent cellular phagocytosis as well as complement-dependent 
cytotoxicity and antibody-dependent cell-mediated cytotoxicity (96). The 
structure of IgG can be split into two parts: the Fc region, which binds to 
FcγRs and the Fab region, which is responsible for recognising and binding 
antigen.  
(c) Complement and complement receptors 
Complement can act as an opsonin or can lyse pathogens directly via the 
membrane attack complex. Complement can become active and interact with 
pathogen surfaces in a number of ways: the classical, alternative or lectin 




Figure 12 Complement system pathways 
The classical pathway activates with binding of C1q to antibody:antigen immune 
complex; the lectin pathway activates when mannose-binding lectin (MBL) binds to 
conserved microbial carbohydrate motifs resulting in the activation of MBL 
associated serine proteases – both of these pathways lead to in the cleavage of C4 
and C2 to form C3 and C5 convertases. Alternative pathway activation results from 
the spontaneous hydrolysis of C3 forming the alternative pathway C3 convertase. 
C3 and C5 convertases generate the key effectors of the complement system: 
opsonins (C3b), anaphylatoxins (C3a, C4a and C5a) and the membrane attack 
complex. Taken from Dunkelberger et al 2009 (114)  
 
C3b binds to complement receptors CR1, CR3 (CD11b/CD18, integrin aMb2) 
and CR4 (CD11c/CD18, integrin aXb2) and the recently discovered CRIg 
(found primarily on Kupffer cells) (114). As well as participating in 
phagocytosis, the complement and Fcγ receptors can modulate the 
expression of one another, for example: activation of C5aR (CD88) leads to 
an increase in the expression of CD16, which is protective in Pseudomonas 
aeruginosa infection; CD88 knockout mice showing a similar phenotype 
 
 50 
during P. aeruginosa infection (increased susceptibility) to CD16 knockout 
mice (115).  
2. Immune dysfunction 
Immune dysfunction is a defining feature of sepsis and plays a major role in 
the pathophysiology of the disease. Historically, sepsis has been thought of 
as a condition with two distinct phases: the initial hyper-inflammatory phase 
followed by a hypo-inflammatory/immunosuppressive stage. Recent studies 
now suggest that both occur simultaneously with the net initial effect being 
hyper-inflammatory (116). There are however competing views as to which 
aspect causes death in patients.  
Figure 13 details two theories regarding immune responses in sepsis; theory 
1 describes a model in which early deaths are caused by excessive 
inflammation whereas late deaths are a result of a failure to clear initial 
infection or the acquisition of secondary infection due to persistent 
immunosuppression (117). Theory 2 describes a model in which protracted 
inflammation driven by the innate immune system leads to organ dysfunction 
and that patients who die, although suffering impaired adaptive immunity, die 
due to the longer and more severe organ injury resulting from persistent 
innate immune driven inflammation (118). Data from post-mortems on 
patients who died from sepsis give greater support to theory 1; patients 
showed decreased production of pro- and anti-inflammatory cytokines, up 
regulation of inhibitory receptors (including PD1), increases in regulatory T 
cell and myeloid-derived suppressor cell populations, and down regulation of 
CD28 and HLA-DR-mediated activation pathways (119). It has also been 
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shown that the rate of positive blood cultures increase in late stages of 
sepsis along with an increase in the number of common opportunistic 
pathogens detected (120).  
 
Figure 13 Competing theories of host immunity in sepsis  




Further evidence to support theory 1 includes the results of surgical sepsis 
patient post-mortems, which showed that 80% of patients had evidence of an 
infectious focus still present at death (121). 
The two-year mortality of patients who survive an initial bout of severe sepsis 
is 1.5 fold higher than other hospitalised patients with mortality varying 
between studies from mortality of 44.9 % to as high as 67 % (122). This 
increase in mortality in survivors is attributed to long-term (nine months – five 
years) sepsis-induced impairment of immune responses: exhibiting both a 
low-level inflammatory status and stunted cytokine production in response to 
inflammatory stimuli, leaving patients more susceptible to subsequent 
infections (123). 
a) Neutrophil dysfunction 
Neutrophil dysfunction is an important factor in the pathophysiology of 
sepsis. Many new treatments for sepsis have been aimed at modifying 
neutrophil responses during sepsis. Severe infection leads to release of 
immature weakly active neutrophils from the bone marrow with decreased 
phagocytosis, decreased chemotactic capability, decreased oxidative burst 
and an increased production of IL-10 (124). Chemotaxis of neutrophils in 
sepsis is impaired to the degree that it has been proposed as possible 
means of evaluating sepsis severity and in major burns (>20% body surface 
area, full thickness burns), where sepsis diagnosis is complicated by 
excessive inflammation, changes in neutrophil migration patterns can predict 
sepsis up to two days before sepsis diagnosis is confirmed (125, 126). Some 
of this neutrophil dysfunction has been shown to be mediated by C5a. 
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Neutrophil activation by C5a can result in the blocking of activation of other 
neutrophils by triggering the release of serine proteases; these then cleave 
CD88 from surrounding neutrophils (127). This is thought to prevent 
excessive neutrophil activation in the context of a small, localised infection, 
but has been implicated in neutrophil dysfunction in both sepsis and the 
cystic fibrosis lung (127). As well triggering the cleavage of CD88, C5a 
binding also inhibits the activity of RhoA and hence polymerization of actin 
and phagocytosis (128, 129). CD88 expression is being explored as a 
possible marker of infection severity in sepsis as reduced expression (due 
receptor cleavage or possibly internalisation) correlates with increased 
infection severity and poorer outcomes in patients (130). This reduction in 
CD88 expression was coupled with a reduction in IL-8 production by 
neutrophils in sepsis patients when stimulated with C5a (130). Anti-C5a 
therapies have been trialled in animals with successfully showing protective 
effects in experimental sepsis but none have yet been developed as far as 
human trials (131-133).   
Due to the capability of neutrophils to produce ROS and NETs they also 
pose a risk to the host; NETosis as been associated with organ dysfunction 
and hence therapies to induce IL-10-mediated inhibition of neutrophil 
infiltration into tissue (95, 134)  
3. Sepsis Treatment  
Patients with sepsis and other severe infections present a significant 
challenge to treatment, often presenting with a diverse range of associated 
co-morbidities and identifying the etiologic agent is often unachievable (135). 
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Over recent years steps have been taken to improve the outcome in severe 
CAP (outlined in the Surviving Sepsis Campaign), yet mortality remains high 
(136). New treatment strategies are therefore urgently needed to 
complement the existing options currently available and limited to antibiotics, 
organ support and source control (137). 
a) Antimicrobials  
“Frapper fort et frapper vite” Paul Ehrlich, 1913 
(Hit hard and fast) 
Since 2002 when the Surviving Sepsis Bundles (Table 7) were introduced 
there has been a movement towards early goal-directed therapy (138). Now 
these bundles have been in place for a number of years it has been shown 
that of the measures introduced only rapid administration of antibiotics has 
had an effect on increasing survival above that of normal care, whilst the 
efficacy of the other measures is controversial (138). Each hour of delay in 
administration of antibiotics is associated with a 7% increase in mortality 
(139). These improvements of course depend on the antibiotic being 
administered being effective against the pathogen being treated, with 
antibiotic resistance increasing failure of antibiotics is possibly going to 
become more common.   
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Table 7 Sepsis bundles. 
Resuscitation bundle (to be achieved within 6 hours from severe sepsis/septic shock 
diagnosis) 
1 - Measure blood lactate 
2 - Blood cultures At least 2 sets of blood cultures before administration of 
antibiotics 
3 - Antibiotics Broad-spectrum antibiotics within 3 hours of admission to the 
emergency department or within 1 hour of admission to other 
hospital units 
4 - SvO2 Measure and achieve central venous oxygen saturation >70% 
5 - Fluid 
resuscitation 
If hypotension and/or blood lactate >4 mmol/L, 1 L crystalloids 
(or 0.5 L of colloid equivalent) in 30 minutes 
6 - Central 
Venous Pressure 
If hypotension despite fluid resuscitation and/or blood lactate >4 
mmol/L, achieve CVP >8 mmHg 
7 - Vasopressors If hypotension not responding to fluid resuscitation, maintain a 
mean arterial pressure >65 mmHg 
Management bundle (to be achieved within 24 hours from severe sepsis diagnosis) 
1 - Lung 
protective 
ventilation 
Maintain inspiratory plateau pressures <30 cmH2O for 
mechanically ventilated patients; avoid a tidal volume >6 mL/kg 
for patients with acute respiratory distress syndrome 
2 - Steroids Administer low-dose steroids for septic shock in accordance 
with a standardized hospital policy 
3 - Drotrecogin 
alfa (activated) 
In accordance with a standardized hospital policy 
(drug withdrawn from market (140)) 
4 - Glucose 
control 
> 4 mmol/L but <8.3 mmol/L 
Adapted from Damiani et al 2015 (141)  
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b) Immune modulating treatments  
Attention is now shifting towards the use of immunomodulatory drugs as 
adjunctive therapies in infectious disease (142). Treatments trialled so far in 
both CAP and sepsis have primarily targeted the hyper-inflammatory phase: 
however statins, steroids and activated protein C have all failed to show 
significant clinical benefit (140, 143, 144). Following on from these failures 
more interest has developed in targeting immunosuppression during 
infection: recombinant GM-CSF, IL-7 and anti-programmed cell death 1 
receptor (PD-1) antibodies are all currently undergoing trials (142). The 
results of phase II clinical trials in Germany on the use of GM-CSF in sepsis 
were reported in 2009 and showed patients treated with GM-CSF had 
reduced time of mechanical ventilation and shorter hospital/ICU stays (145). 
Phase III trials in France are currently recruiting for a study investigating the 
effects of GM-CSF on rates of infection in ICUs (146). IL-7 is currently in 
phase II clinical trials in the US investigating the ability of IL-7 to restore 
lymphocyte counts in sepsis patients (147). Anti-PD-1 antibodies are still in 
the pre-clinical stages of development but in vitro studies have shown that 
blockade of the receptor decreases apoptosis and improves immune cell 
function in septic patients (148). The anti-PD-1 antibody pembrolizumab, 
produced by Merck already has FDA approval for treatment of melanoma so 
could quickly progress to human trials (149).   
New treatment strategies are desperately needed to complement the existing 
options available that are currently limited to antibiotics, organ support and 
source control (137).  
 
 57 
D. P4 therapy 
One possible new immunomodulatory treatment is P4 therapy; a combination 
passive immunotherapy along with the immunoactivating peptide P4.  
1. Passive immunotherapy 
Passive immunotherapy – the transfer of functional antibodies from an 
immunised host to a susceptible host  
a) History 
The transfer of antibodies as a treatment of infection has been used for over 
a century; early preparations used for passive immunotherapy were relatively 
crude, utilising serum from immunised animals and were associated with a 
high incidence of side effects, known as “serum sickness”, in patients (up to 
50%) ranging from relatively mild symptoms such as itching and rashes to 
more serious symptoms such as hypotension and shock (150, 151). Despite 
the severe side effects observed, by the 1930s serum therapy had become 
the standard therapy for pneumococcal pneumonia, although this treatment 
required early administration, having little effect if administered after 4 to 5 
days after the onset of symptoms. Passive immunotherapy, along with 
potentially severe side effects during the treatment of pneumococcal disease, 
was also hindered by serotype specificity - a mixture of serum, from the 







ensure efficacy in the absence of a specific diagnosis with regards to 
pneumococcal serotype, which more often than not was unknown at the time 
of treatment (152). Passive immunotherapy was also an expensive therapy 
to produce, as it required not only the animals used to produce the immune  
serum but also required in vivo testing for efficacy and potency of each batch 
to determine treatment doses (152). Fleming’s discovery of penicillin in 1928 
and subsequent mass production of the drug pioneered by researchers lead 
by Howard Florey in the 1940s resulted in a decline in serum therapy in 
favour of penicillin with its broader specificity, more favourable side effect 
profile and cheaper production (152).  
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Table 8. Comparison of immune serum, human monoclonal antibodies and 




Antibody based therapies have developed over the years as production 
techniques have improved and there are now an immense number of 
monoclonal antibody (MAb) therapies being utilised in other fields such as 
oncology and inflammatory disorders, yet usage in bacterial infection is 
limited. Table 8 compares immune serum, human MAb and chemotherapy 
(such as antibiotics) in the treatment of infection. 
b) Intravenous immunoglobulin in passive immunotherapy  
Intravenous immunoglobulin (IVIG) is already used in the treatment of 
several autoimmune and inflammatory diseases but has potential for use in 
infectious disease (153). Utilising IVIG for the treatment of severe bacterial 
infections has the potential to bridge the gap between human mAb and 
conventional chemotherapy by offering a treatment with broad specificity, low 
toxicity, easy administration, consistent pharmacokinetics and diverse 
antimicrobial actions. Unfortunately the use of IVIG in clinical trials in the 
treatment of sepsis thus far have show conflicting results, with outcomes 
varying depending on the dose and the IVIG preparation used in each study 
(154, 155). As well as inconclusive results in clinical trials, IVIG is an 
expensive drug with a cost of £20,850 per quality adjusted life year, just 
above the £20,000 limit for treatments on the NHS (156). It is also not totally 
understood how IVIG acts during treatment for sepsis as there are numerous 
components of the immune response to infection whose actions can be 
modified by the administration of IVIG (detailed in Figure 14) (112).  
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Figure 14 Fc and Fab mediated IVIG activity 
The top panel shows the Fab mediated mechanisms of immunomodulation: 
antibody-dependent cytotoxicity, blockade of cell surface receptors, the 
neutralisation of cytokines and scavenging of anaphylatoxins. The bottom pane 
show Fc mediated mechanism of immunomodulations: the blocking/saturation of cell 
surface receptors (such as FcγR) , modulation of FcγR expression and expansion of 
Treg cells. Taken from Schwab et al. 2013 (112) 
 
Effectiveness of IVIG as an opsonin during passive immunotherapy is limited 
by the requirement for frequent large doses of antibody (at significant 
financial cost) and the capability of the host’s cellular response to utilise the 




2. P4 peptide 
The P4 is a 28 amino acid peptide derived from the lipoprotein 
pneumococcal surface adhesin A (PsaA), which is being investigated due to 
its immunomodulating effects. 
PsaA is a highly conserved molecule, which is partially exposed on the 
pneumococcal surface, although the majority of the molecule is concealed by 
capsular polysaccharides. PsaA functions as a manganese transporter in the 
pneumococcus and is also a putative adhesin binding to E-cadherin (158).      
Figure 15. P4 peptide  
Crystal structure, molecular weight and amino acid sequence of P4 peptide. 
 
P4 peptide was developed when the Center of Disease Control and 
Protection were looking for the functional epitope within PsaA, which allowed 
binding of the pneumococcus to epithelial cells with the intention of then 
using that epitope to develop treatments targeted at blocking bacterial 
binding through PsaA. A series of peptides were produced based on the 
sequence of PsaA, those of interest were named P4, P6 and P7. P4 is 
homologous to the PsaA sequence with a conservative substitution of two 
amino acid: a pair of aspartic acid to a lysine and arginine (detailed in Figure 
 MW  = 3254.8 Da 
 Amino acid residues 251–278 





16) this substitution was outside of areas in the sequence thought to be of 
functional importance (159).  
P6 and P7 are truncations of P4, with P6 being truncated at the N-terminus 
whilst P7 was truncated at the C-terminus (sequences shown in Figure 16). 
They found that fluospheres coated in both P4 and P7 had high binging to 
nasopharyngeal cells (Detroit 562) whereas P6 had low binding (159). They 
went on to treating nasopharyngeal cells with 20 µg/well of P4 peptide before 
adding 1 μm fluorescent polystyrene spheres (fluospheres) coated in rPsaA, 
which resulted in a 95.5% inhibition of the rPsaA fluospheres to 
nasopharyngeal cells (159). 
 
 
Figure 16 Comparison of P4, P6 and P7 sequence with PsaA sequence. 
Amino acid sequences of PsaA, P4, P6 and P7 – orange boxes indicate areas 
thought to be functional domains of PsaA. Blue box indicates location of amino acid 
substitution.    
When treatment with P4 was tried out on nasopharyngeal cells with live S. 
pneumoniae, rather than blocking binding, increased adhesion and invasion, 
electron micrographs of these cells showed that those treated with P4 had 
large vacuoles containing internalised material, which was thought to be 
suggestive of a strong cellular activation. Increases in adhesion/invasion 
were not serotype specific and were also observed with Streptococcus 





Figure 17 Transmission electron micrographs of P4-treated and non-treated 
Detroit 562 cells (1900×) 
Panel A. Non-treated Detroit 562 cells. Panel B. Cells treated with P4. Arrows 
indicate large vacuoles containing internalised material (160).   
This proposed cellular activation was also observed in undifferentiated 
human neutrophils (HL-60), mouse macrophages (RAW 261.4) and freshly 
isolated human blood neutrophils.  In addition to cellular activation it was 
observed that P4 treatment led to an increase in basic fibroblast growth 
factor (FGF-β) and a reduction in IL-6, IL-8 and Vascular endothelial growth 
factor (V-EGF) secretion by nasopharyngeal cells. No differences were 
observed in the secreted levels of cytokines IL-1, IL-10, TNF-α, IFN-γ, and 
GM-CSF (160).  
Following on from these studies P4 was used in opsonophagocytosis assays 
with HL-60, IVIG and complement to look at the effect of the peptide on 
phagocytosis of pneumococci. P4 significantly enhanced the phagocytosis of 
pneumococci by HL-60s in a dose dependent manner but its effect was 
dependent on the presence of antibody and complement as the response 




Figure 18 Effect of removing assay components from OPK on P4 
enhancement of phagocytosis in human alveolar macrophages. 
“OPK” = all components are included (macrophage, bacteria, antibody, 
complement), “no antibody” = without the presence of antibody, “no complement” = 
without the presence of complement, and “FcγR block” = where Fcγ receptors were 
occupied by IgG prior to the assay. Taken from (162) 
Table 9. Published P4 in vivo research.  
Year  Main findings 
2008 
(161) 
P4 and antibody treatment via I.P. injection lead to 60% survival, I.V 





Treatments with P4 and IVIG in combination with antibiotics reduced 
the dosage of antibiotic required and lead to increased survival when 
compared to antibiotics alone.   
Animals which survived pneumococcal pneumonia after treatment with 
P4 and IVIG were re-infected and treated a second time with P4 and 









Treatment with P4 and IVIG rescued mice from fatal Staphylococcus 




Mice were challenged with influenza before infection with 






Mice infected with pneumococcus were treated with P4 and IVIG. Mice 
receiving an intranasal dose at an early time point (12 and 18 hrs) saw 
significant improvements in survival from 0% for controls to 100% for 
treated mice at 48 hours post infection. Mice that received a later dose 
intravenously (24 and 30 hours) saw significant improvements in 





Having shown in vitro efficacy at enhancing phagocytosis, studies moved on 
to in vivo models of infection. Animal studies so far have looked at treatment 
of S. pneumoniae (with and with out influenza) and Staphylococcus aureus 
with P4 peptide in combination with antibodies and have shown treatment 
lead to increased survival. These studies are summarized in Table 9. From 
the in vivo work it was established that treatment with P4 peptide led to an 
increase in the surface expression of CD32/16 (FcγRII/III) on both 
neutrophils and macrophages of mice both during infection in in naïve mice 
(167).  
Human ex vivo studies showed that treatment of alveolar macrophages and 
peripheral blood neutrophils with P4 peptide in an OPK assay also resulted in 
increased phagocytosis of pneumococci in healthy volunteers from both the 
UK and Malawi (162). Although populations showed significant increases in 
phagocytosis, the baseline killing of macrophages from UK volunteers was 
higher and treatment led to greater improvements in phagocytosis than were 
seen in Malawian volunteers (162). As well as increased phagocytosis this 
study also showed increased intracellular oxidation; this increase in 
intracellular oxidation was only significantly increased during OPK assay 
however and not in cell treatment directly with P4 only (162). This study also 
showed no increases in inflammatory cytokines or markers of cellular 
activation on alveolar macrophages treated with P4 following an OPK assay 
(162). Based on these in vitro and in vivo studies a hypothesis for P4 
mechanism of action was formed (represented in Figure 19); this hypothesis 
was that the enhancement in FcγR coupled with the administration of 
pathogen specific IgG (in the form of IVIG) leads to increased phagocytosis 
 
 66 
of bacteria during infection and hence a decreased bacterial burden and 
improvements in survival. As of yet the mechanism by which P4 increases 
FcγR expression is unknown. 
Figure 19 P4 enhances phagocytosis of IVIG opsonised bacteria through 
increased expression of FcγR  
By using P4 with IVIG (P4-IVIG therapy) as the source of IgG, for 
opsonisation of pathogens, this treatment has the potential for use in 
numerous infections as IVIG contains antibodies specific to a wide range of 
common pathogens. This would be beneficial in the treatment of sepsis and 
other severe bacterial infections were the causative agent is often not known 
when treatment is initiated and patients are often suffering from depletion of 
immunoglobulins (168).      
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E. Aims and objectives 
1. Gram negative infections 
Having shown efficacy in the treatment of Gram positive infections (S. 
pneumonia and MRSA) with P4 peptide treatment, the first aim of this study 
was to explore the use of P4 in combination IVIG in the treatment of Gram 
negative infections, namely E. coli and K. pneumoniae most commonly 
associated with severe invasive infections such as sepsis. This will be 
achieved through the development and use of murine models of sepsis from 
which I will determine the effects of P4 treatment on bacterial load, neutrophil 
responses to infection, and overall inflammation and host survival patterns.         
2. Ex vivo CAP  
The second aim of this study was to assess ex vivo, the capacity of P4 
peptide to enhance bacterial phagocytosis by peripheral blood neutrophils 
and alveolar macrophages in a cohort of patients admitted to ICU with 
community acquired pneumonia. As well as looking at phagocytic killing as a 
primary endpoint for the study I aimed to determine the effects of ex vivo P4 
treatment on neutrophil cell surface receptor expression, inflammation and 
whether patient clinical measures would give an indication as to which 
patient groups would most likely benefit from P4 treatment. 
3. Mechanism of P4 action  
The third aim of this study was to investigate the effect of P4 on receptor 
expression on the neutrophils of naïve mice in an attempt to learn more 
about the mechanism of P4 function.   
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Chapter II. In vivo murine study of 
effects of P4 peptide during severe 






Previous studies have shown the in vivo efficacy of P4 peptide in the 
treatment of acute pneumonia and sepsis caused by the Gram-positive 
pathogens Streptococcus pneumoniae and Staphylococcus aureus (MRSA) 
(161, 164, 165, 167). This study goes on to look at the efficacy of P4 
treatment in severe Escherichia coli infection.   
1. Animal Model 
For this study an animal model of E. coli peritoneal infection that rapidly 
progresses to sepsis was developed in order to assess treatment efficacy. 
This model was used for both survival and time pointed experiments. Models 
utilised also assessed the efficacy of P4 treatment as an adjunctive therapy 
in combination with antibiotic treatment. An intra-peritoneal infection model 
was chosen as this site is the third most common site of initial infection in 
sepsis, with treatment failure being associated with persistent or recurrent 
infection and high mortality.  
2. Cell surface marker and cytokines 
Tissue and blood from time pointed experiments were collected for flow 
cytometry analysis of cell surface markers and measurement of cytokines in 
order to monitor the effect of treatment on the immune response to infection. 
The cytokines chosen for analysis were CXCL1, IL-10 and C5a. CXCL1 was 
chosen as it regulates the production of a number of cytokines, chemokines 
and adhesion molecules essential for neutrophil recruitment and activation as 




Figure 20 CXCL1 -mediated signaling cascades leading to bacterial clearance 
in the organs in response to polymicrobial sepsis 
(1 and 2) CXCL1 production by hematopoietic and resident cells as a result of 
interaction with pattern recognition receptors. (3, 4 and 5) CXCL1 activates NF-κB, 
MAPK leading to upregulation of cell adhesion molecules (ICAM-1) and 
cytokines/chemokines, which results in neutrophil recruitment to the tissues from the 
bloodstream. (6, 7 and 8) CXCL1 regulates the production of IL-17 (IL-17A), 
resulting in the production of CXCL2/MIP-2 and IL-6 and hence neutrophil 
recruitment. (9) CXCL activates NADPH oxidase leading to the production of ROS, 
eventual NETosis and augmenting phagocytosis.(10) Enhanced neutrophil 
recruitment and activation leads to bacterial clearance. From Jin et al. 2014(169) 
 
IL-10 was chosen as a cytokine of interest due the role it plays in immune 
modulation, both beneficial and detrimental effects have been reported for IL-
10 in sepsis, on the one hand it can blunt the pro-inflammatory response, 
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reducing TNF and IFN-γ whilst on the other hand it has been shown to 
negatively effect splenocyte function (170-172). IL-10 has also been shown 
to play a major role in determining when animals enter a phase of irreversible 
shock and has shown to be protective in models of polymicrobial sepsis, with 
the timing of intervention being important and blocking of IL-10 being 
beneficial in the later stages of infection (173, 174). 
C5a was measured due to the reported role in neutrophil dysfunction which 
was discussed in the introduction (Chapter I.C.2.a).  
Cell surface markers investigated in this study included CD64, CD32/16, and 
CD88. CD64 and CD32/16; the FcγRs were measured as the proposed 
mechanism of P4 function is a modulation of FcγR expression. CD88 is the 
receptor for complement. CD88 is of interest because of the role of C5a-
CD88 binding and its effects on neutrophil function as well as being a 




B. Methods and Materials 
1. Media Preparation  
a) LB Agar    
400 ml of distilled water was mixed with 8 g of Luria broth powder (Sigma, 
UK L3022) and 6 g of agar (Oxoid, UK LP0011) before autoclaving at 121°C 
for 15 minutes. Plates were poured once agar had cooled to 56°C. Plates 
were stored at 4°C until use.  
b) LB Broth 
400 ml of distilled water was mixed with 8 g of LB broth powder (Sigma, UK 
L3022) before autoclaving at 121°C for 15 minutes. BHI broth was cooled 
before use and stored at room temperature. 
2. Bacterial strain and inoculum preparation  
E. coli RS218, a K1 strain isolated from a case of neonatal meningitis was 
used for all E. coli infection models. This strain was gifted by Dr Stephen 
Smith, Trinity College, Dublin.   
Infections were carried out with mid-log cultures. Strains were streaked on to 
LB agar plates from frozen stocks and incubated at 37°C for 16-18 hours. 
The following day universal tubes containing 5 ml of LB broth were 
inoculated from the plate and incubated at 37°C, 200 rpm for 16-18 hours. 
Following the 16-18 hour incubation 500 μl was subcultured into 20 ml of LB 
broth and adjusted to an OD600 of 0.1. The culture was incubated at for 37°C, 
200 rpm for 1-2 hours until reaching an OD600 of 0.5, cultures were 
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centrifuged at 3000 rpm for 5 minutes, the supernatant discarded and the 
pellet resuspended in PBS, this was repeated and the culture then 
resuspended at 2 x 108 CFU per ml. Doses were plated onto LB agar to 
confirm inoculum CFUs .  
3. Animal model techniques 
All animal work was completed at the University of Liverpool under Home 
Office project licence No.40/3602. Female CD-1 mice aged between 6-7 
weeks were used for all experiments.  
a) Euthanasia and animal monitoring  
During experiments animal behaviour was monitored to assess progression 
of infection and wellbeing of animals, scoring system is described in Table 
10. In accordance with the home office licence under which experiments 
were performed, mice were culled when they reached lethargy ++. 
b) Schedule 1 culls 
Schedule 1 culls were carried out on animals during survival studies. Mice 
were culled by cervical dislocation or alternatively mice were place in an 
anaesthetics box and the CO2 concentration increased slowly over a 6 
minute period until mice stopped breathing and cervical dislocation was 




Table 10 Animal model scoring 
Score Description 
Normal Mouse is displaying normal behaviour and coat condition. 
Hunched + Mouse displays slight arching of back. 
Hunched ++ Mouse displays very arched back 
Starry + Coat looks poorly groomed around neck area with upright 
hairs. 
Starry ++ Coat looks poorly groomed over whole animal. 
Lethargy + Mouse is moving slowly around cage. 
Lethargy ++ Mouse does not move without encouragement. 
Moribund Mouse is poorly groomed, not moving and has laboured 
breathing. 
 
c) Cardiac puncture under terminal anaesthesia  
Mice were placed in an anaesthetics box and with oxygen set to 0.8 L/min 
and isofluorane at 5%, mice were monitored, an absence of reflex 
responses, whisker twitching and a decreased respiratory rate confirmed 
anaesthesia. Mice were transferred to an anaesthesia cone and the paws 
and tail firmly pinched to ensure a lack of pain response. A 23 gauge needle 
attached to a syringe was inserted under the rib cage into the heart at a 45° 
angle and the syringe pulled back until 1-2 ml of blood is collect. Mice were 
then immediately culled by cervical dislocation.  
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d) Animal procedures  
(i) Intraperitoneal injection 
Intraperitoneal injections were used for the infection of animals during the E 
coli infection models and for administration of IVIG in all animal studies. Mice 
were manually restrained: held by the scruff with the thumb and forefinger 
non-dominant hand, securing tail with the remaining fingers. Mice were then 
tilted downward at a 45 ° angle and injected in either the left or right the lower 
quadrant of the abdomen, away from the midline to avoid puncturing the 
bladder with a 27 gauge insulin syringe.  
(ii) Intravenous injection 
Mice were warmed for 5-10 minutes prior to injection in a heating box to 
dilate the veins. Mice were secured in a restraint device and the tail held with 
slight traction and a 27 gauge needle inserted parallel to the vein (either of 
the lateral veins shown in Figure 21) and advanced 2-3 mm into the lumen 
before slowly injecting. If the infection is performed correctly the vein should 
blanche as the substance is injected. 
Figure 21 Anatomy of murine tail   
Lateral veins 
Ventral artery  Vertebra   
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e) Infection and monitoring  
The prepared dose was administered by intraperitoneal injection into mice as 
a 50 μl dose, using a 27g insulin syringe (detailed in methods and materials 
chapter).  Because of the extremely rapid onset of disease symptoms mice 
were monitored hourly from administration of infectious dose. Animals were 
culled when they reached ++ lethargy (details of scoring in methods and 
materials).   
f) P4 treatment  
P4 peptide and IVIG were administered at one and three hours post 
infection. P4 peptide was administered via a 50 μl intravenous injection into 
the tail vein at a concentration of 2 mg/ml dissolved in DEPC treated water. 
This dose was chosen as it was what had been previously used successfully 
in the treatment of S. pneumoniae sepsis (167). IVIG was administered by a 
100 μl intraperitoneal injection (I.P.) of Gamunex-C (Grifols, Spain), 100 mg 
of protein per ml. IVIG was injected I.P. as trials carried out at the CDC 
showed that the mice better tolerated it when compared with intravenous 
injection of of IVIG. Control animals received an injection of equivalent 
volume of sterile PBS. 
g) Antibiotic treatment    
Tazocin (Pfizer, USA) – piperacillin/tazobactam – was used in experiments at 
a dose of 9 mg/mouse, which equated to ¼ of the human equivalent dose. 
Tazocin was injected via the tail vein, 50 μl dissolved in DEPC treated water 
at the same time points as P4 treatment. Control animals received an 
 
 77 
injection of equivalent volume of sterile PBS. Tazocin was chosen as it is a 
broad-spectrum antibiotic, which is commonly used for peritonitis and 
pneumonia.  
4. Tissue collection 
(a) CFUs 
Tissue being processed for the determination of CFUs only was 
homogenised with a T10 homogeniser (IKA, Germany) in 3 ml of PBS, short 
5 second bursts at a high speed were used until the tissue suspension 
appeared homogeneous. The Miles and Misra technique was used to 
determine CFU numbers from mouse tissues. Using a 96 well plate, 20 µl of 
bacterial suspension was serially diluted into wells each containing 180 µl of 
phosphate buffer solution (PBS). Each well was thoroughly mixed before 
transferring 20 µl to the next dilution; a sterile pipette tip was used for each of 
the dilutions. Dilutions were continued from 101 to 106. Agar plates were 
marked into six sections and labelled from 10 to 106, 20 µl of each dilution 
was plated in triplicate onto the corresponding segment. Plates were then 
incubated overnight at 37°C. Colonies were counted in sections containing 
between 30-300 colonies. Colony forming units (CFU) from the original 
samples were calculated using the following equation:  
CFU ml⁄ =  Number of colonies in sector ×  dilution factor ×(1000 60⁄ ) 
b) Flow cytometry  
Tissue being processed for flow cytometry was placed in a 40 μm cell 
strainer on top of a 50 ml tube and forced through the membrane with the 
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plunger from a 2 ml syringe. Cell strainers were rinsed through with 5 ml of 
PBS. Cells were pelleted by centrifuging at 300 g and the supernatant 
discarded (or stored at -80 °C for later cytokine analysis). Red blood cells 
were lysed using red blood cell lysis buffer (eBioscience, UK) according to 
the manufacturers instructions. Cells were centrifuged at 300 g, the 
supernatant discarded and the cells resuspended in PBS, 2 % FBS ready for 
staining for flow cytometry.  
Single cell suspensions were divided equally into the wells of a 96 round 
bottom plate. For each sample there was an unstained well, isotype control 
well and a stained well. Plates were centrifuged at 300 g and the supernatant 
removed. The antibodies detailed in Table 11 with corresponding isotype 
controls (BIolegend, USA), were used for flow cytometry analysis of mouse 
leukocytes. All antibodies were used at a dilution of 1:250 in staining buffer 
(PBS supplemented with 2% FBS).  





101325 APC anti-mouse CD16/32 
101245 
Brilliant Violet 510™ anti-mouse/human 
CD11b 
135809 PE/Cy7 anti-mouse CD88 (C5aR) 
123417 
APC/Cy7 anti-mouse CD21/CD35 
(CR2/CR1) 
103127 Alexa Fluor® 700 anti-mouse CD45 
139303 PE anti-mouse CD64 (FcγRI) 




Each well then had 50 μl of stain (or staining buffer for unstained controls) 
added and the wells were mixed. Cells were incubated for 20 mins at 4°C. 
Cells were then washed 3 times in staining buffer by centrifuging at 300 g, 
discarding supernatant and resuspending in 200 μl of staining buffer. Cells 
were then either immediately analysed by flow cytometry or were fixed with 
Cytofix (BD, UK) according to the manufacturers instructions, for analysis the 
following day. Sample acquisition was performed on the BD LSR II (BD 
Biosciences, USA) and analysis was performed with FlowJo 8.7 (Tree Star, 
USA).     
c) Cytokine analysis  
ELISA assays for CXCL1, IL-10 and C5a (R&D systems, UK) were 
performed according to the manufacturers instructions. Blood was collect in 
heparin and nafamostat mesylate (Sigma, UK) to prevent complement 
activation.  
5. Statistical analysis 
Statistical analysis was performed with Prism 5 (Graphpad Software, USA), 




C. Model development  
The mouse model of E. coli infection developed for this project, involved 
injection of E. coli RS218 into the peritoneal space of mice. Various doses 
were trialled during the establishment of this model.  
Figure 22 shows the CFUs detectable in the blood of CD-1 mice infected at 
various doses. The dose of 1 x 107 CFU/mouse was chosen as lower 
infectious doses were clear by the mice within 48 hours without treatment.  
Infection with 1 x 107 CFUs progressed rapidly, with CFUs detectable in the 
blood at 3 hours post infection (Figure 22). Untreated mice progressed to 
lethargy quickly with subjects being culled from eight hours post infection. 
Other mouse strains were trialled to see if the model could be extended 
beyond 8 hour survival for untreated animals. No difference was observed in 
survival times between CD-1 mice and Balb/C, C57B6 or MF1 mouse strains.   
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Figure 22 Blood CFUs of mice infected with E. coli over 48 hrs 
Blood CFUS of mice (n=3 per group) infected with E. coli  via I.P. injection at dose 
between 1 x 105 and 1 x 107 CFU/mouse. Blood was collected from the tail vein at 




1. Single dose P4 treatment  
In order to assess the viability of P4 as a treatment for E. coli infection I 
carried out preliminary experiments aimed at determining if a P4-IVIG 
treatment could reduce the bacterial burden in the blood, lungs and spleen of 
mice. Mice were infected with 107 CFUs of E. coli via I.P. injection followed 
by a single treatment of P4 (50 μl of 2 mg/ml I.V.) and IVIG (100 μl of 100 
mg/ml I.P.) at 1 hour post infection. Experiments tracking bacterial burden in 
the blood during the model development showed that by 3 hours post 
infection mice already had between 106-107 CFU/ml of blood and reached 
the humane endpoint within 8-12 hours (Figure 22); as the model was known 
to progress quickly, the earliest logistically possible time point, 1 hour post 
infection, was chosen for treatment. Animals were then culled at four and 7 
hours post infection in order to collect the blood, lungs and spleen and 
determine the CFUs present. The  hours post infection cull was chosen 
based on the model development data, which showed dissemination of the 
infection into the blood by 3 hours post infection. The 7 hour post infection 
cull was chosen as the last time point at which there was 100% survival of 
untreated animals during model development. Treatment doses of P4 and 
IVIG were based on those used to successfully treat mice in models of S. 
pneumoniae sepsis (167).  
Treatment with a single dose of P4 and IVIG led to substantial decreases (1 
log) in CFUs detected in the blood, lungs and spleen at both the four and 7 
hour time points (Figure 23 and Figure 24), with the seven hour time point 
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showing a 2 log decrease in CFU burden in the blood and spleen (blood 
mean PBS = 4.4 x 108 CFU/ml vs P4-IVIG = 8.6 x 106 CFU/ml, p=0.0004, 
spleen mean PBS = 4.8 x 105 CFU/mg vs P4-IVIG = 3.1 x 105 CFU/mg, 
p=0.02) and a 5 fold decrease in lung CFUs (mean PBS = 5.0 x 104 CFU/mg 
vs P4-IVIG 1.0 x 104 CFU/mg, p=0.007).  
During the model development it was observed that mice infected with lower 
doses of E. coli (106 and 105 CFU/mouse) had 106 CFU/ml of blood or less at 
3 hours post infection and that the bacterial burden would subsequently 
decline to undetectable levels over 48 hours without intervention; those with 
CFUs in the blood over 106 CFU/ml succumbed to their infection. Although 
decreases in CFUs were promising, the number of CFUs in the blood and 
spleen of mice that received P4 treatment was static between the two time 
points, remaining at above 106 CFU/ml in the blood. In addition to this the 
number of CFUs detected in the lung had increased by close to 1 log 
between the two time points (mean four hour = 1.3 x 103 CFU/mg vs 7 hours 
= 1.0 x 104 CFU/mg). With this in mind I concluded that a single dose regime 
was unlikely to lead to significant increases in survival and either concurrent 





Figure 23 Single dose treatment of P4 peptide in severe E. coli infection model 
– Blood CFUs 
Mice n=10 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) 
and I.P. with 100 μl of IVIG (100 mg/ml), while control animals received injections of 
PBS of equal volume. Mice were culled 4 and 7 hours post infection and blood 
collected for determination of CFUs. Plotted as mean and SEM. Analysis by two-






























































Figure 24 Single dose treatment of P4 peptide in severe E. coli infection model 
– Tissue CFUs 
Mice n=10 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) 
and I.P. with 100 μl of IVIG (100 mg/ml), while control animals received injections of 
PBS of equal volume. Mice were culled 4 and 7 hours post infection and tissue 
collected for determination of CFUs. Plotted as mean and SEM. Analysis by two-

























































































































2. Single dose combination treatment  
a) Tazocin testing 
The single dose P4 treatment experiments showed reductions in CFUs 
detected in the blood, lungs and spleen of P4-IVIG treated mice, however did 
not show reductions that were likely to lead to an increase in survival. 
Following these experiments I then went on to looked at P4 treatment in 
combination with antibiotics. The antibiotic chosen for these experiments was 
Tazocin; a dose of 9 mg/mouse was selected as ¼ of the human equivalent 
dose (based on an average mouse weight of 25 g). To test this dose animals 
were infected with 107 CFU of E. coli before treating one hour post infection 
with 9 mg/mouse of Tazocin via I.V. injection, mice were bled at four hours 
post infection and culled at seven hours post infection to monitor the bacterial 
burden in the blood.  
Treatment with a single dose of Tazocin at 1 hour post infection lead to a  
reduction in CFUs recovered from blood of over 2 log (mean PBS = 6.8x107 
CFU/ml vs Tazocin = 4.3x105 CFU/ml at the four hour time point; PBS = 9.7 
x108 CFU/ml vs Tazocin = 1.6 x106 CFU/ml at the seven hour time point, 
two-way repeated measures ANOVA p<0.0001) (Figure 25).  
Although this antibiotic concentration lead to a significant reduction in CFUs it 
did not clear the infection and the numbers of CFUs detected were 
increasing between the two time points. It was decided to continue with this 
dose in the combination treatment experiments as it was sufficient to reduce 
the numbers of CFUs but not so high that it would mask any potential benefit 
seen with P4 treatment.  
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Figure 25 Blood CFU after single treatment of Tazocin in E. coli infection 
model 
Mice n=5 per group were infected with 1 x 107 CFU E. coli via intraperitoneal route. 
1 hour post infection mice were treated I.V. with 50 μl of Tazocin (9 mg/mouse) or 
50 μl of PBS. Mice were tail bled at four hours post infection and culled at seven 
hours post infection. Plotted as mean and SEM. Blood was collected for 












































b) Bacterial burden and survival 
Having established that a single dose of P4 treatment was insufficient to treat 
the infection and identified a suitable concentration of Tazocin for use in the 
model I then went on to test the two treatments in combination. Treatment a 
single dose of P4-IVIG alongside Tazocin was trialled in the E. coli mouse 
model with both agents being administered at one hour post infection; P4 
and Tazocin were both administered via I.V. injection whilst the IVIG was 
administered via I.P. injection. Initial experiments sought to establish the 
effect of combination treatment on the bacterial burden at four and seven 
hours post infection as well as survival over a 24 hour period. As in previous 
experiments, animals were infected with 107 CFU of E. coli before treating 
one hour post infection with either PBS, P4-IVIG, Tazocin or the combination 
of P4-IVIG and Tazocin. Mice were bled at four hours post infection and 
culled at seven hours post infection to monitor the bacterial burden in the 
blood and lungs. A second set of mice were monitored over a 24 hour period 
as a survival experiment, with mice being culled when they reached their 
humane end point of lethargy. 
Treatment with the two drugs in combination appeared to have an additive 
effect; the decrease in CFUs being approximately the sum of the decrease in 
CFUs of each of the two treatments individually (Figure 26). There were 
significantly lowers numbers of blood CFUs detected for all three treatments 
at seven hours post infection compared with PBS treated mice: P4-IVIG + 
Tazocin = 1.7 x106 CFU/ml (p<0.005), Tazocin = 1.5 x 108 CFU/ml (p<0.05), 
P4-IVIG = 4.5 x 107 CFU/ml (p<0.005) and PBS = 5.3 x 108 CFU/ml. The four 
hour time point showed the same trend but no individual pairings were 
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statistically significant (two-way ANOVA p=0.04). The lung CFUs showed the 
same trend as the blood CFUs but was not statistically significant (p=0.1, 
one-way ANOVA) (Figure 27).   
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Figure 26 Single dose P4 therapy with antibiotics in E. coli infection model – 
Blood CFU 
Mice n=5 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) 
and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice 
received PBS injections of equal volume. Mice were tail bled at 4 hours post 
infection and culled at 7 hours post infection. Blood was collected for determination 
of CFUs. Plotted as mean and SEM. Analysis by two-way ANOVA and Bonferroni 
post tests p=0.0491 (** p<0.005, * p<0.05). 
 
Figure 27 Single dose P4 therapy with antibiotics in E. coli infection model – 
Lung CFU 7 hours post infection 
Mice n=5 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) 
and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice 
received PBS injections of equal volume. Mice were culled at seven hours post 
infection. Lung tissue was collected for determination of CFUs. Plotted as mean and 




















































































In the survival model mice were monitored over a 24 hour period. The mean 
survival time was significantly higher for mice treated with either of the three 
treatment groups when compared to the untreated (PBS) control: Tazocin 
alone 15.8 hours (p<0.005), P4-IVIG alone 16.8 hours (p<0.005) and P4-
IVIG + Tazocin 19 hours (p<0.0001) compared with PBS treated mice 8.4 
hours (one-way ANOVA and Bonferroni’s multiple comparison test, 
p=0.0004). There was no difference in mean survival between the three 
treatment groups (Figure 28, Figure 29 and Table 12).  
The survival percentage at the end of the 24 hour period was 40% for the P4-
IVIG + Tazocin treatment group but was 0% for all other treatment groups. 
Blood was collected at the time of death for mice in the survival experiments 
and the CFUs in blood determined; it was observed that some of the mice 
treated with Tazocin and P4-IVIG + Tazocin had lower CFUs than you would 
expect at the time of death (Figure 30). This could suggest that factors such 
as excessive inflammation or high levels of endotoxins could be contributing 
to mortality in addition to the bacterial burden.  
As survival within the P4+IVIG and Tazocin group was still low, at 40% over 
24 hours, I decided to increase the number of doses administered to try and 




Figure 28 Single dose P4 therapy with antibiotics in E. coli infection model - 
Survival  
Mice n=5 per group were infected with 1 x 107 CFU E. coli via intraperitoneal 
infection. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (2 
mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control 
mice received PBS injections of equal volume. Mice were monitored for signs of 
disease and culled when they reached ++ lethargic. 
 
 
Table 12 Single dose P4 therapy with antibiotics in E.coli infection model –
Survival time 
 PBS Tazocin P4-IVIG P4-IVIG + 
Tazocin 
Group size 5 5 5 5 
Mean 8.40 16.80 15.80 19.00 
Minimum 8.00 14.00 15.00 15.00 




Figure 29 Single dose P4 therapy with antibiotics in E. coli infection – Survival 
time 
Mice n=5 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (1 mg/ml) 
and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice 
received PBS injections of equal volume. Mice were monitored for signs of disease 
and culled when they reached ++ lethargic. Survival time in hours and the median 
plotted. Analysed by Kruskal-Wallis test and Dunn’s multiple comparison test *** 
p<0.001, ** p<0.005 
 
Figure 30 Time of death blood CFUs 
Mice n=5 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. 1 hour post infection mice were treated I.V. with 50 μl of P4 peptide (1 mg/ml) 
and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice 
received PBS injections of equal volume. Mice were monitored for signs of disease 
and culled when they reached ++ lethargic. Blood was collect at time of death and 
CFUs determined.     
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3. Double dose P4 and antibiotic combination treatment 
a) Bacterial burden and survival  
The next treatment schedule tested was a double dose P4 and antibiotic 
combination. A second dose was added to the treatment schedule to try and 
improve survival in the model beyond the 40% survival seen with a single 
dose. For this set of experiments the Tazocin + IVIG and IVIG alone groups 
were added after observing that mice in the Tazocin alone treatment group 
which were culled upon reaching ++lethargic often had considerably lower 
CFUs at time of death than PBS groups or treatments that did not include 
Tazocin (Figure 30). The reasoning behind this was that if the mice were 
succumbing to the infection despite clearing significant numbers of bacteria 
then perhaps they were having a severe inflammatory response which could 
be mediated by the via the anti-inflammatory properties of IVIG.  
(1) Survival 
As the single dose experiments (Figure 26 and Figure 27) had shown the 
combination of P4-IVIG and Tazocin were effective at reducing the bacterial 
burden the survival experiments were performed first. As with previous 
experiments mice were infected with 107 CFU/mouse of E. coli, treatments 
were administered at one and four hours post infection with P4 and Tazocin 
administered via I.V. injection and IVIG via I.P. injection. Mice were then 
monitored over a 24 hour period and culled when they reached their humane 
end point.  
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The P4-IVIG + Tazocin group and the Tazocin + IVIG had 24 hour survival of 
55% and 60% respectively Survival for PBS, IVIG, Tazocin and P4-IVIG 
treated mice were 0%, 10%, 11% and 28% respectively (Figure 31). The 
mean, minimum and maximum survival times for each group are detailed in 
Table 13. All treatments bar IVIG alone had significantly longer mean survival 
than PBS controls.. P4-IVIG + Tazocin had significantly longer mean survival 
times than PBS, IVIG and Tazocin alone (p<0.0001). Tazocin + IVIG had 
significantly longer mean survival than IVIG alone (p<0.05) but did not show 
a significant difference compared to Tazocin alone. There was no significant 
difference between mean survival times for P4-IVIG + Tazocin and Tazocin + 
IVIG (Figure 32).  
The mean survival time and survival percentage showed improvements with 
the double dose compared with the single dose; survival percentages over 
24 hours increased from 40% to 55% for P4-IVIG and Tazocin and the 
survival percentage for Tazocin increased from 0% to 60% (Figure 28 and 
Figure 31). However, mean survival times did not show improvements: 
P4+IVIG and Tazocin mean survival time single dose = 19 hours vs. double 
dose = 20.6 hrs, Tazocin mean survival time single dose = 16.8 hours vs. 
double dose = 13.8 hours (Table 12 and Table 13).  
As there was no significant difference between the survival percentages or 
mean survival times of mice treated with P4-IVIG and Tazocin versus those 
treated with Tazocin and IVIG I went on to look at the bacterial load and 
inflammatory markers. 




Figure 31 Double dose P4 therapy with antibiotics in E. coli infection model – 
Survival 
Mice n=18  (except IVIG and Tazocin + IVIG n=10) per group were infected with 1 x 
107 CFU E. coli via the intraperitoneal route. 1 and 4 hours post infection mice were 
treated I.V. with 50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. 
with 100 μl of IVIG (100 mg/ml). Control mice received PBS injections of equal 
volume. Mice were monitored for signs of disease and culled when they reached ++ 
lethargic. 
 
Table 13 Double dose P4 therapy with antibiotics in E. coli infection model – 
Survival time 
 





Group size 18 10 18 10 18 18 
Mean 8.972 12.30 13.83 19.19 15.25 20.69 
Minimum 6.000 9.000 9.000 10.50 9.000 12.00 






PBS vs IVIG ns 
PBS vs Tazocin * 
PBS vs P4-IVIG ** 
PBS vs P4-IVIG + Tazocin *** 
PBS vs Tazocin + IVIG *** 
IVIG vs Tazocin ns 
IVIG vs P4-IVIG ns 
IVIG vs P4-IVIG + Tazocin *** 
IVIG vs Tazocin + IVIG * 
Tazocin vs P4-IVIG ns 
Tazocin vs P4-IVIG + Tazocin *** 
Tazocin vs Tazocin + IVIG ns 
P4-IVIG vs P4-IVIG + Tazocin * 
P4-IVIG vs Tazocin + IVIG ns 
P4-IVIG + Tazocin vs Tazocin + IVIG  ns 
Figure 32 Double dose P4 therapy with antibiotics in E. coli infection model – Survival 
time 
Mice n=18 (except Tazocin + IVIG n=10) per group were infected with 1 x 107 CFU E. coli via 
the intraperitoneal route. 1 and 4 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control 
mice received PBS injections of equal volume. Mice were monitored for signs of disease and 
culled when they reached ++ lethargic. Survival time in hours and the mean plotted. 
Analysed by one-way ANOVA test, p<0.0001 and Bonferroni’s multiple comparison test – 
right hand table (*** p<0.0001, ** p<0.005, * p<0.05) 
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(2) Bacterial burden 
Having seen an improvement in survival percentages for mice treated with a 
double dose of treatment but not an improvement in mean survival time I 
then went on to look at the bacterial burden. Mice were infected with 107 
CFU/mouse of E. coli via I.P. injection; mice were then treated at one hour 
and four hours post infection with P4 and Tazocin administered via I.V. 
injection and IVIG via I.P. injection. At seven hours post infection mice were 
culled and Blood, lungs and spleen tissue were collected and processed for 
the determination of CFUs. IVIG alone was not included as a group as it 
showed no benefit over PBS treated mice in survival studies. 
(a) Blood CFUs  
All treatments containing Tazocin showed a statistically significant reduction 
in CFUs compared to PBS controls (p value of specific comparisons as 
determined by Dunn’s multiple comparison indicated in Figure 33). 
Differences between the three groups containing Tazocin; Tazocin alone, 
Tazocin-IVIG and P4-IVIG + Tazocin were not statistically significant 
although the differences observed in blood CFUs were far larger than in 
other tissues, with Tazocin + IVIG showing far superior bacterial clearance; 
Tazocin only median = 8.2 x 104, IQR 3.1 x103- 2.9 x 105, Tazocin-IVIG 
median = 0, IQR 0-12, P4-IVIG + Tazocin median = 1.9 x 103 , IQR 77 – 1.5 x 
104 (Figure 33). 
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(b) Lung CFUs 
As was seen in the blood, all treatments containing Tazocin showed a 
statistically significant reduction in CFUs when compared to PBS controls 
and P4-IVIG (p value of specific comparisons as determined by Bonferroni’s 
post test indicated in Figure 34). Differences between the three groups 
containing Tazocin; Tazocin alone, Tazocin + IVIG and P4-IVIG + Tazocin 
were not statistically significant. The numbers of CFUs detected in the lungs 
were far closer for the Tazocin containing groups than was seen in the blood 
with the medians for the three groups ranging from 10 to 30 CFU/ml (Figure 
34). The number of CFU recovered from the lungs of P4-IVIG treated mice 
did not differ greatly between single and double dose treated mice with a 
slight increase in the double dose (mean log CFU single dose = 4.3 vs. 
double dose = 5.2); this could suggest that treatment with P4-IVIG was not 
as effective it penetrating tissues as antibiotics.   
As the bacterial burden was significantly reduced with a double dose of 
treatment when compared to a single dose of treatment and increased the 
percentage of survivors over 24 hours, but did not significantly alter the mean 
survival time of subjects. In an attempt to explain the discordance between 
these three measures I then went on to look at inflammatory markers, cell 
populations and endotoxins. 
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Figure 33 Double dose P4 therapy with antibiotics in E. coli infection model –Blood CFU 
Mice n=18 (except IVIG and Tazocin + IVIG n=10) per group were infected with 1 x 107 CFU E. coli via the intraperitoneal route. 1 and 4 hours 
post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). 
Control mice received PBS injections of equal volume. Mice were culled at 7 hours post infection and tissue collected for determination of 




Figure 34 Double dose P4 therapy with antibiotics in E. coli infection model – Lung CFU 
Mice n=18 (except IVIG and Tazocin + IVIG n=10) per group were infected with 1 x 107 CFU E. coli via the intraperitoneal route. 1 and 4 hours 
post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). 
Control mice received PBS injections of equal volume. Mice were culled at 7 hours post infection and tissue collected for determination of 
CFUs. Analysed by one-way ANOVA and Bonferroni post test with mean and SEM *** p<0.0001 
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b) Inflammatory markers  
I went on to look at the plasma levels of CXCL1, IL-10 and C5a in mice that 
had been infected with E. coli and treated with a double dose of P4-IVIG and 
Tazocin. I looked at the time point of seven hours post infection in line with 
the time point used for assessing bacterial burden. There were two aims to 
these experiments: looking to see if the different treatment combinations 
resulted in differences in inflammatory marker levels and to see if the levels 
of these markers gave any clue as to why mice that had low levels of CFUs 
reached their humane endpoint and had to be culled.  
As with previous experiments mice were infected with 107 CFU/mouse of E. 
coli and treated one and four hours post infection before culling at seven 
hours post infection for blood collection.   
Significantly lower levels of CXCL1 (p<0.005), were detected in mice treated 
with P4-IVIG + Tazocin compared with Tazocin alone (Mean P4-IVIG + 
Tazocin = 181.2 ng/ml vs. Tazocin 824.0 ng/ml, (Figure 35). It should be 
noted however that all the CXCL1 levels were very high.  
The levels of IL-10 detected in plasma were lower in all mice with treatments 
containing IVIG although these differences were only significant between 
PBS and Tazocin only treated mice, which had the highest levels (mean IL-
10 PBS = 609 pg/ml, Tazocin = 499 pg/ml) and P4-IVIG and Tazocin-IVIG 
treated mice which had the lowest levels (mean IL-10 Tazocin-IVIG = 90 
pg/ml, P4-IVIG = 57 pg/ml) (Figure 36).  
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There was no difference between groups in the level of C5a detected in 
plasma (Figure 37). These samples were treated with nafamostat mesylate 
(FUT-175, Sigma, UK) a serine protease inhibitor that prevents the activation 
of C5 and production of C5a ex vivo, however it is still possible that ex vivo 
activation has occurred that would effect the reliability of this measurement 
(175). C5a and its corresponding receptors are rapidly internalised upon 
binding so a lack of difference in plasma concentrations could also be a 






Figure 35 Double dose P4 therapy with antibiotics in E. coli infection model – Plasma CXCL1 
Mice n=8 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal route. 1 and 4 hours post infection mice were treated I.V. with 
50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice received PBS injections of equal 
volume. Mice were culled at seven hours post infection and blood collected for determination of cytokine concentrations in plasma. Plotted as 




Figure 36 Double dose P4 therapy with antibiotics in E. coli infection model – Plasma IL-10 
Mice (PBS =11, Tazocin= 13, Tazocin+IVIG=8, P4-IVIG=8, P4-IVIG+Tazocin=17 per group) were infected with 1 x 107 CFU E. coli via the 
intraperitoneal route. 1 and 4 hours post infection mice were treated I.V. with 50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. 
with 100 μl of IVIG (100 mg/ml). Control mice received PBS injections of equal volume. Mice were culled at seven hours post infection and 
blood collected for determination of cytokine concentrations in plasma. Plotted as mean and SEM. Analysed by Kruskal-Wallis test and Dunn’s 




Figure 37 Double dose P4 therapy with antibiotics in E. coli infection model – Plasma C5a 
Mice n=8 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal route. 1 and 4 hours post infection mice were treated I.V. with 
50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice received PBS injections of equal 
volume. Mice were culled at seven hours post infection and blood collected for determination of cytokine concentrations in plasma. Plotted as 
mean and SEM. Analysed by Kruskal-Wallis test and Dunn’s multiple comparison test p=0.7613 (*** p<0.0001, ** p<0.005, * p<0.05) 
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c) Cell populations 
Previous work looking at P4 treatment of S. pneumoniae infection and 
administration of P4 to naïve mice has shown that P4 treatment resulted in 
an increase on the percentage of neutrophils found in the blood as well as an 
increase in expression of FcγRs on neutrophils; with this in mind I performed 
experiments to look at the neutrophil populations in the blood of E. coli 
infected mice treated with Tazocin or Tazocin and P4-IVIG in combination 
(167). In addition to FcγR expression I looked at the expression of CD88 
(C5aR) as binding of C5a to this receptor was been linked to neutrophil 
dysfunction as well as modulation of FcγR expression (115, 128). As with 
previous experiments mice were infected with 107 CFU/mouse of E. coli and 
treated one and four hours post infection before culling at seven hours post 
infection for blood collection. Blood samples were washed and stained with 
antibodies before sample acquisition on a BD LSR II flow cytometer. 
Significantly higher percentages of neutrophils were seen in Tazocin (p<0.05, 
median = 60%) and P4-IVIG + Tazocin (p<0.0001, median = 72%) treated 
groups when compared to PBS treated mice (median = 31%) (Figure 38). 
When analysed in isolation the difference between Tazocin and P4-IVIG + 
Tazocin was statistically significant (p<0.03, unpaired t-test). Both high and 
low levels of circulating neutrophils have been associated with poor 
prognosis; low neutrophil count indicates possible immunosuppression 
whereas an overly high neutrophil count is suggestive of excessive 
inflammation (176).   
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Figure 38 Double dose P4 therapy with antibiotics in E. coli infection – % 
Neutrophil (CD45+, CD11b+, Gr-1+) of CD45+ cells 
Mice n=10 per group were infected with 1 x 107 CFU E. coli via intraperitoneal route. 
1 and 4 hours post infection mice were treated I.V. with 50 μl of P4 peptide (2 
mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control 
mice received PBS injections of equal volume. Mice were culled at seven hours post 
infection and blood collected for staining of neutrophils to determine neutrophil 
(CD45+, CD11b+, Gr-1+) % of CD45+ cells. Plotted as median and IQR. Analysed 
by Kruskal-Wallis test and Dunn’s multiple comparison test *** p<0.0001, * p<0.05  
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In order to look at the expression levels of FcγRs on neutrophils, cells were 
gated using anti-CD45, GR-1 and CD11b antibodies. Expression of CD64 
and CD32/16 were measured on these neutrophil populations. CD32/16 
antibodies were used, as there is no antibody commercially available that 
can distinguish between the CD32 and CD16 receptors in mice. No 
difference was seen in the level of CD64 (FcγRI), between groups although 
there was a trend towards lower expression with PBS<Tazocin<P4-IVIG + 
Tazocin; the median value for CD64 expression was highest in PBS treated 
mice (MFI = 354) followed by Tazocin (MFI = 275) and P4-IVIG + Tazocin 
had the lowest expression (MFI = 225) (Figure  39- top panel). This decrease 
in CD64 expression as opposed to being related directly to augmentation of 
Fc receptor expression by P4 treatment could reflect the severity of infection 
as high CD64 has been shown clinically to be an indicator of infection and 
sepsis (177, 178). Expression of CD64 is also highest in immature cells, 
which could indicate that the PBS treated groups have a higher proportion of 
immature neutrophils in the blood stream compared with treated groups.  
Expression of CD32/16 (FcγRII/III) on neutrophils was significantly higher in 
both the Tazocin (p<0.05, median MFI = 6950) and P4-IVIG + Tazocin 
(p<0.005, median MFI = 7343) groups when compared to the PBS (median 
MFI = 3918) treated group (Figure 39 - bottom panel). These increased 
levels of CD32/16 could be due to augmentation of FcγR by P4 peptide 
treatment but could also be indicative of a more mature neutrophil population 
in Tazocin and P4-IVIG + Tazocin groups or alternatively a result of CD16 
downregulation during sepsis; CD16 decreases with increased infection 




Figure 39 Double dose P4 therapy with antibiotics in E. coli infection model  – 
Neutrophil receptor expression FcγRs 
Mice n=10 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. One and four hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were culled at 7 
hours post infection and blood collected for staining of neutrophils (CD45+, CD11b+, 
Gr-1+) to determine expression levels of CD32/16 (FcγRII/III) and CD64 (FcγRI). 
Plotted as median and IQR. Analysed by Kruskal-Wallis test and Dunn’s multiple 
comparison test ** p<0.005, * p<0.05  























Expression of CD88 was also measured; isotype controls were used for 
these experiments as previous studies have reported P4 altering Fc receptor 
expression, which could effect the measurement of non-Fc recptors through 
non specific binding of the Fc region to Fcγ receptors (166, 167). 
CD88 expression was significantly higher in both the Tazocin (p<0.05, 
median MFI = 42668) and P4-IVIG + Tazocin (p<0.05, median MFI = 40609) 
groups when compared to the PBS (median MFI = 24870) treated group 
(Figure 40). Decreased CD88 is a marker of increased severity and binding 
of C5a to its receptor can have negative implications for neutrophil function. 
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Figure 40 Double dose P4 therapy with antibiotics in E. coli infection model  – 
Neutrophil receptor expression CD88  
Mice n=10 per group were infected with 1 x 107 CFU E. coli via the intraperitoneal 
route. One and four hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were culled at 7 
hours post infection and blood collected for staining of neutrophils (CD45+, CD11b+, 
Gr-1+) to determine expression levels of CD88. Plotted as median and IQR. 




d) Endotoxins – LPS 
After observing that P4-IVIG and Tazocin treatments only lead to a modest 
extension in survival time of around 10 hours, despite significant reductions 
in CFUs in the blood, LPS was measured from the plasma of animals culled 
at seven hours post infection. LPS is a potent driver of inflammation and 
plasma levels can be affected by antibiotic treat meant so this was measured 
to see if it could be a possible factor driving mortality in the model (180).   
Plasma endotoxin levels as measured using a Limulus amebocyte lysate 
assay (LAL). As expected endotoxin levels were elevated in all mice (healthy 
levels should be below detection limit). No significant difference was seen 
between any of the groups (Figure 41).   
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Figure 41 Double dose P4 therapy with antibiotics in E. coli infection model – 
Serum endotoxin levels  
Mice n=5 per group were infected with 1 x 107 CFU E. coli via intraperitoneal route. 
1 and 4 hours post infection mice were treated I.V. with 50 μl of P4 peptide (2 
mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control 
mice received PBS injections of equal volume. Mice were culled at seven hours post 
infection and blood collected for determination of endotoxin concentrations in serum. 
Plotted as median and IQR. Analysed by Kruskal-Wallis test and Dunn’s multiple 




E. Results Summary  
Treatment with a single dose of P4-IVIG one hour post infection lead to 
significant reductions in CFUs in both blood and organs at seven hours post 
infection when compared to PBS treated controls but the number of CFUs in 
the blood were increasing when compared to the 4 hour time point (Figure 
23).  
A combination treatment of Tazocin (25% of human equivalent dose) and P4-
IVIG at one hour post infection lead to a greater decrease in CFUs compared 
to either treatment alone with mean CFUs of 7.5 x 107 for Tazocin alone, 2.5 
x 107 for P4-IVIG and 8.9 x 105 for the combination treatment, compared to 
2.7 x 108 for untreated (PBS) mice (Figure 26). This in turn translated into a 
significant increase in mean survival over a 24 hour period post infection 
rising from 8.4 hours for untreated controls to 19 hours for those treated with 
P4-IVIG + Tazocin, P4-IVIG and Tazocin alone had mean survival times of 
16.8 and 15.8 hours respectively.  An increase in the percentage of animals 
surviving to 24 hours was observed, with survival increasing from 0% for 
untreated controls to 20% for P4-IVIG + Tazocin, survival for P4-IVIG and 
Tazocin alone survival was 0% (Figure 28). 
To determine if host survival could be improved further, an increased dosing 
schedule was trialled with the addition of a second treatment dose: the first 
remaining at one hour post infection with the second at four hours post 
infection.   
Increasing the P4 dosing schedule from a single dose to a double dose did 
not effect the mean survival time over the 24 hours the mice were monitored 
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but it did effect the survival percentage at 24 hours: P4-IVIG survival 
increased from 0% to 27%, Tazocin alone from 0% to 11% and P4-IVIG + 
Tazocin from 20% to 55%, untreated (PBS) survival remained at 0% (Figure 
31). The double dose regime also resulted in a greater reduction in mean 
CFUs in the blood at 7 hours post infection compared with a single dose: 
Tazocin treatment showing a drop of over 3 logs with a second dose (7.5 x 
107 to 2.1 x 104 CFU/ml), P4-IVIG a modest decrease of just under a log (2.5 
x 107 to 5.7 x 106 CFU/ml) and there was a drop of over 3 logs for P4-IVIG + 
Tazocin in combination from (8.9 x 105 to 816 CFU/ml) (Figure 33). 
Treatment with a double dose of P4 peptide in combination with IVIG and 
Tazocin lead to significantly higher 24 hour survival than treatment with 
Tazocin alone. However, this combination treatment had equivalent efficacy 
to Tazocin + IVIG treatment (Figure 31). Between these three treatments 
there was no significant difference in the CFUs in blood or lungs at seven 
hours post infection (Figure 33 and Figure 34). 
Table 14 Comparison of single and double dose treatment of P4-IVIG in 
combination with antibiotics- Blood and lung CFUs 
 
Blood 7hr Log CFU 







8.19 6.31 7.30 5.35 - 
Double 
Dose 
8.50 4.33 6.76 2.91 0.95 
Lung 7hr Log CFU 







4.93 4.32 4.37 1.85 - 
Double 
Dose 
5.44 1.42 5.20 1.10 0.72 
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Table 14 shows a comparison of CFUs detected in the blood and lungs at 
seven hours post infection for both single and double doses of treatment. All 
treatments apart from PBS and P4-IVIG showed a decrease in CFUs. This 
could suggest that without the antibiotics present a further dose of P4-IVIG 
does not lead to improvements in bacterial killing, perhaps because the 
immune response has been exhausted.   
Where the three treatments containing Tazocin did differ was the cytokine 
response to infection; treatment with P4-IVIG +Tazocin resulted in the lowest 
levels of CXCL1, significantly lover than treatment Tazocin alone (p=0.005). 
Differences between other pairings of treatment groups were not significant. 
It should be notes that the level of CXCL1 detected was very high for all 
treatment groups.  
IL-10 levels were significantly higher in PBS and Tazocin treated mice than 
those treated with Tazocin-IVIG or P4-IVIG. There was no significant 
difference between IL-10 levels in P4-IVIG + Tazocin treated mice and any 
other group, with levels sitting midway between the two high groups and the 
two low groups.  
There was no difference in the levels of C5a between treatment groups, with 
a large degree of spread in the data. Inflammatory marker data is 





Table 15 Summary of CXCL1, IL-10 and C5a mean plasma levels at seven 
hours post infection for mice treated with a double dose of P4-IVIG and 
antibiotics in combination 
 









243.8 824.0 181.2 378.8 583.8 
 IL-10 
pg/ml 
609.2 499.4 257.8 90.01 57.11 
C5a 
pg/ml 
40958 54931 44254 51210 33700 
 
Mice treated with Tazocin or P4-IVIG + Tazocin had a higher percentage of 
neutrophils in the blood than those treated with PBS (p=0.05 and p=0.0001 
respectively) The difference between neutrophil percentages between 
Tazocin and P4-IVIG + Tazocin treated mice was 12%, if analysised in 
isolation this difference was significant (p=0.03 t-test).  
Expression of receptors on neutrophils from Tazocin and P4-VIG + Tazocin 
treated groups showed higher levels of both CD32/16 (FcγRII/III) and CD88 
than in PBS treated groups. The levels of CD64 (FcγRI) expressed on 
neutrophils was not significantly different between groups but was lowest in 
P4-IVIG + Tazocin treated groups followed by Tazocin treated groups, with 
the highest expression in the PBS treated groups.  
To summarise the double dose of P4-IVIG and Tazocin lead to increased 
survival and decreased bacterial burden compared to a single dose but was 
not superior to a double dose of Tazocin and IVIG in combination, which also 
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had high survival over 24 hours (Tazocin-IVIG = 60%, P4-IVIG + Tazocin = 
55%) and superior clearance of bacteria.  
The difference in the levels of IL-10 and CXCL1 are difficult to interrupt 
based on a single time point as it is unknown where they are increasing or 
decreasing as the infection progresses and also how the consumption rate of 
these molecules is effecting levels detectable in the plasma.   
Significant differences in neutrophil percentages and expression of FcγR and 
CD88 on neutrophil were only seen between groups that received treatment 
versus PBS controls which could suggest that these difference reflect a 
difference in infection severity at the given time point as opposed to a drug 
induced change in receptor expression.  
The severity of the model necessitated early sacrifice (in line with the terms 
of the Home Office licence), thus limiting the opportunity of dosing. To better 
assess the efficacy of P4-IVIG a less severe model would be of benefit.   
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F. Discussion  
The model of E. coli systemic infection developed for this project, was 
extremely acute, with quite an aggressive progression into sepsis; CFUs 
were detectable in the blood within one hour of peritoneal infection and PBS 
treated animals reached lethargy (humane endpoint of infection) within ten 
hours.  
1. Survival and bacterial burden 
Single dose treatment with P4 peptide and IVIG lead to a significant 
reduction in the number of CFUs in the blood, lungs and spleen at seven 
hours post infection compared to PBS treated mice however the CFUs 
recovered from these mice was increasing between four and seven hours 
post infection. With a bacterial burden of around 107 CFU/ml in the blood at 
seven hours post infection these mice were unlikely to survive, for this 
reason antibiotics were introduced into the model. This model of P4-IVIG 
treatment in combination with antibiotics is also more in line with how future 
clinical use is envisaged; with P4 therapy being adjunctive to, not replacing, 
conventional antimicrobial therapies. Tazocin was chosen after consultation 
with an ICU physician whom indicated that Tazocin would be the antibiotic of 
choice for an abdominal infection suspected to be due to a Gram-negative 
pathogen. The dose of 9 mg/mouse (25% of the human equivalent dose) was 
selected after initial dose testing confirmed that it was insufficient to clear the 
infection alone therefore still allowing for an effect of P4 therapy to be shown.  
Addition of Tazocin to the model had a synergistic effect with P4-IVIG 
treatment in combination with Tazocin leading to a decline in CFUs greater 
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than either of the two separately, with significantly fewer CFUs recovered 
with P4-IVIG + Tazocin than from treatment with Tazocin alone. 
This combination treatment also leads to improvements in survival, all mice 
treated with Tazocin alone reached lethargy (humane endpoint) with 16 
hours post infection, all mice treated with P4-IVIG with 24 hours, whilst 40% 
of mice treated with the combination of P4-IVIG + Tazocin survived to 24 
hours.  
At the end of these experiments it was observed that the number of CFUs 
recovered from Tazocin and P4-IVIG + Tazocin treated mice at the time of 
death where not as high as would be expected considering the degree of 
lethargy and were considerably lower than those treated with PBS or P4-
IVIG. Alongside this, the rapid onset of symptoms during infection led to the 
suspicion that endotoxins (LPS) might be playing a significant role in the 
pathophysiology of the infection. 
A second dose was added to the treatment schedule in an attempt to 
improve outcomes in the model, along with the Tazocin + IVIG, this group 
was added due to the suspicion that LPS was contributing significantly to the 
pathophysiology during infection. 
 Treatment with all three drug combinations that included Tazocin: Tazocin, 
Tazocin + IVIG and P4-IVIG + Tazocin led to significantly lower numbers of 
CFUs in the blood, lungs and spleen when compared to PBS treat mice. 
There wasn’t however a statistically significant difference in the number of 
CFUs recovered the three groups. There was a difference in 24 hour survival 
time between Tazocin and P4-IVIG + Tazocin in combination. However, this 
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difference, albeit non-significant, was also evident when treating with Tazocin 
and IVIG in combination. There was no difference in survival time between 
P4-IVIG + Tazocin and Tazocin + IVIG.  
The reason for a poor survival despite significant reductions in CFUs with 
Tazocin, P4-IVIG + Tazocin and Tazocin + IVIG treatment was likely due to 
animal suffering from septic shock. In septic shock patients suffer from 
intractable vasodilation, microvascular thrombosis, increased adhesion of 
leukocytes to venules and increased vascular permeability as a result of 
excessive inflammation, coagulation dysfunction and endothelial damage; all 
of which lead to impaired tissue perfusion and organ failure (138). These 
patients would receive interventions to support their failing physiology such 
as intravenous fluids, vasopressors, inotropic drugs and mechanical 





2. Inflammatory Markers 
a) CXCL1  
All mice had very high levels of CXCL1, which has been shown to be 
essential to survival in polymicrobial sepsis models (cecal ligation and 
puncture) (169). The levels of CXCL1 were slightly lower in P4-IVIG + 
Tazocin treated mice than in the other groups, although this difference was 
only significant between P4-IVIG + Tazocin and Tazocin alone. The 
difference in median values was ten fold between the two groups. This 
difference could be interpreted in a number of ways; in experiments with 
human epithelial cells in tissue culture P4 was shown to decrease the 
expression of IL-8 (human homolog of CXCL1), so one could conclude that 
the lower levels of CXCL1 are due to direct modulation of cytokine 
production, this unlikely to be the case though as there was no reduction 
seen in mice treated with just P4-IVIG (182). An alternative hypothesis is that 
there is less CXCL1 because there is a lower bacterial burden in this group, 
again this is unlikely as the Tazocin + IVIG group, which showed the lowest 
bacterial burden still had very high levels of CXCL1. Another possibility is 
that IL-10-mediated attenuation of CXCL1 production, this has been 
observed in with LPS induced CXCL1 and Candida albicans infection, where 
IL-10 destabilises CXCL1 mRNA and de novo synthesis of the protein (183-
185). This could be possible as the P4-IVIG + Tazocin treatment group had 
relatively high of IL-10 and a similar bacterial burden to the Tazocin + IVIG 
group which had lower IL-10 and higher CXCL1. However the Tazocin only 
treated group had the second highest level of IL-10 and the highest level of 
CXCL1. The final theory to explain the lower levels of CXCL1 in the P4-IVIG 
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+ Tazocin is that it is bound to the CXCR2 receptor on neutrophils and that 
the higher proportion of neutrophils in the blood of P4-IVIG + Tazocin has 
resulted in a higher turnover of the cytokine. This could also help explain the 
disparity between the high neutrophil levels and low CXCL1 in this group. All 
of these theories may contribute to the lower CXCL1 levels in P4-IVIG + 
Tazocin but to help delineate which factors are important more time points 
would be needed in order to establish the temporal order of cytokine 
production and their effects.              
b) IL-10 
The highest levels of IL-10 were seen in PBS treated and Tazocin treated 
mice. High levels of IL-10 in the PBS treated mice seems logical as with high 
CFUs you would expect high LPS. In the Tazocin treated mice there was 
also high IL-10 despite these mice having significantly lower numbers of 
CFUs, this could due to treatment with Tazocin leading to endotoxcin release 
(112, 186). The P4-IVIG and Tazocin-IVIG group had significantly lower 
levels of IL-10 than the PBS and Tazocin treated groups, despite the P4-IVIG 
group higher numbers bacterial and the Tazocin treated group having the 
possibility of antibiotic-induced endotoxcin release. One possible theory that 
could explain the lower levels of IL-10 is that the IVIG is mopping up the LPS, 
the problem with this being the IVIG has been shown to increase IL-10 
production by macrophages in response to LPS (187). The intermediate 
levels of IL-10 in P4-IVIG + Tazocin treated mice are also difficult to explain, 
neutrophils can be induced to produce IL-10 after direct contact with LPS-
stimulated regulatory T-cells and this group did have the highest proportions 
of neutrophils (188).  
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With the protective role IL-10 can play in sepsis in mind it would be important 
to establish the timing of IL-10 induction and cell types producing IL1-0 in this 
model as well as levels of IL-10 before and after treatment to determine how 
the various treatments are effecting production (173, 174).  
c) C5a 
C5a has a very short in vivo half-life (2-3 mins) which is thought to be due to 
the rapid binding and internalisation through C5a receptors so plasma levels 
of C5a may not reflect the levels being produced (189) (190). There was little 
difference in plasma C5a between group however the PBS group had 
significantly lower levels of CD88 , which could suggest that it was being 
produced at higher quantities but had a higher turnover rate.  
3. Cell populations 
a) Neutrophil percentages  
Neutrophil percentages were significantly higher in Tazocin and P4-IVIG + 
Tazocin treated mice compared to those treated with PBS, with the highest 
levels being in the P4-IVIG + Tazocin treated group. The factors driving this 
increase in neutrophils is not clear from this study as the levels of CXCL1 
were lowest in the this group and there were no significant differences in the 
levels of C5a. In further studies it would be important to investigate a broader 
range of neutrophil chemoattractants as well as cytokines involved in 
stimulating production of neutrophils such as GM-CSF and G-CSF to see 
how P4 treatment affects these.  
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b) FcγR expression 
Expression of receptors on neutrophils from Tazocin and P4-VIG + Tazocin 
treated groups showed a pattern of receptor expression that is indicative of a 
lower severity of infection compared with the PBS treated group: higher 
levels of CD32/16 (FcγRII/III), which suggests a more mature neutrophil 
population and lower levels of CD64 (FcγRI) which suggests the infection is 
less severe than in PBS treated mice at this time point (178). Decreased 
CD64 expression could also be interpreted as indirect evidence of increased 
phagocytosis as the receptor is internalised during phagocytosis (191). CD64 
expression also deceases during maturation in the bone marrow, so high 
levels could again suggest that the PBS treated neutrophils are less mature 
and those treated with Tazocin and P4-IVIG + Tazocin.  Whether these 
changes can be attributed directly to augmentation of receptor expression by 
the P4 peptide or are the result of a lower infectious burden is less clear. 
c) CD88  
Mice treated with Tazocin or P4-IVIG and Tazocin had higher levels of CD88 
on their neutrophil. Reduced expression of CD88 during infection has been 
shown to correlate with increased infection severity and can be used as 
prognostic markers for survival in sepsis patients (130). Higher levels of 
CD88 in the Tazocin and P4-IVIG + Tazocin treated groups could therefore 
be suggestive of a lower infection severity in these groups.  
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4. Endotoxcin (LPS)  
Endotoxin levels in serum were tested to see if different treatments led to 
different levels of endotoxin being released into the circulation leading to 
altered levels of inflammation. No difference in endotoxin levels was 
observed between any of the treatment groups despite significantly different 
bacterial loads. Although the LAL assay is very sensitive, serum proteins can 
interfere with the assay rendering it less reliable, hence more testing would 
be required to determine whether there is a true difference between 
endotoxin levels (192).  
5. Summary 
To summarise P4 treatment in this model of E. coli infection was successful 
to an extent; treating with P4-IVIG lead to a decrease in CFUs detected in 
mice but significant increases in survival time were only seen with the 
addition of antibiotics and were not superior to treatment with Tazocin and 
IVIG in combination. Considering the swift decline of health in animals after 




Chapter III. In vivo murine study of 
effects of P4 peptide during 







The previous chapter focused on an animal model of E. coli infection via the 
peritoneal route; this infection model gave an acute, very severe infection, 
this chapter goes on to look at P4 therapy in the treatment of K. pneumoniae 
pulmonary infection. K. pneumoniae was chosen as the pathogen as it is the 
second most common cause of Gram negative bloodstream infection after E. 
coli, accounts for 10% of hospital acquired bacterial pneumonias and in 
regions where it is particularly prevalent (Taiwan and South Africa) it has a 
higher mortality than S. pneumoniae (38-40).  
1. Animal Model 
For this study an animal model of K. pneumoniae respiratory infection (with 
sepsis secondary to pneumonia) was developed in order to assess treatment 
efficacy. This model was similar to the S. pneumoniae model of invasive 
pneumococcal disease published by Bangert et al. with mortality for 
untreated subjects at 80-100% and a progression to sepsis between 24 and 
30 hours post infection. This model was used for both survival and time 
pointed experiments. Models utilised also assessed the efficacy of P4 
treatment as an adjunctive therapy in combination with antibiotic treatment.    
2. Cell surface marker and cytokines 
Tissue and blood from time pointed experiments were collected for flow 
cytometry analysis of cell surface markers and measurement of cytokines in 
order to monitor the effect of the effect of treatment on the immune response 
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to infection. The same cell surface and inflammatory markers were used as 





B. Methods and Materials 
1. Media preparation 
a) Blood Agar 
400 ml of distilled water was mixed with 16 g of blood agar base 2 (Oxoid 
CM0271) before autoclaving at 121°C for 15 minutes. Once the agar had 
cooled to approximately 56°C, 20 ml of defibrinated horse blood (Oxoid 
SR0050) was added to give a final concentration of 5% blood agar and then 
poured into sterile petri dishes. Plates were stored at 4°C until use. 
b) Brain Heart Infusion Broth 
400 ml of distilled water was mixed with 14 g of brain heart infusion (BHI) 
broth powder (Oxoid CM1135) before autoclaving at 121°C for 15 minutes. 
BHI broth was cooled before use and stored at room temperature.  
For BHI with serum – an aliquot of heat inactivated foetal bovine serum (FBS 
– Sigma F9665) was thawed and added to broth aseptically at the 
appropriate concentration.  
2. Bacterial strain and inoculum preparation  
K. pneumoniae ATCC 43816, a serotype 2 strain was purchased from LGC 
Standards, UK.    
Infections were carried out with mid-log cultures. Strains were streaked on to 
5 % blood agar plates from frozen stocks and incubated at 37°C for 16-18 
hours. The following day universal tubes containing 5 ml of BHI broth were 
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inoculated from the plate and incubated at 37°C, 200 rpm for 16-18 hours. 
Following the 16-18 hour incubation 500 μl was subcultured into 20 ml of LB 
broth and adjusted to an OD600 of 0.1. The culture was incubated at for 37°C, 
200 rpm for 1-2 hours until reaching an OD600 of 0.5, cultures were 
centrifuged at 3000 rpm for 5 minutes, the supernatant discarded and the 
pellet resuspended in PBS, this was repeated and the culture then 
resuspended at 2 x 106 CFU per ml. Doses were plated onto 5 % blood agar 
to confirm inoculum CFUs .  
3. Mouse Strains 
Female CD-1 mice aged between 6-7 weeks were used for all experiments.  
4. Infection and monitoring  
The prepared inoculum was administered by intranasal instillation of 50 μl 
dose distributed evenly between the two nares (detailed in section II.B). Mice 
were monitored at regular intervals from administration of infectious dose. 
Animals were culled when they reached ++ lethargy (details of scoring in 
methods in section II.B).   
5. P4 treatment  
P4 peptide and IVIG were administered at 24 and 30 hours post infection via 
a 50 μl intravenous injection into the tail vein at a concentration of 2 mg/ml 
dissolved in DEPC treated water. IVIG was administered by a 100 μl 
intraperitoneal injection of Gamunex-C (Grifols, Spain), 100 mg of protein per 
ml. Control animals received an injection of equivalent volume of sterile PBS. 
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6. Antibiotic treatment    
Tazocin (Pfizer, USA) – piperacillin/tazobactam – was used in experiments at 
a dose of 9 mg/mouse, which equated to ¼ of the human equivalent dose. 
Tazocin was injected via the tail vein, 50 μl dissolved in DEPC treated water 
at the same time points as P4 treatment. Control animals received an 
injection of equivalent volume of sterile PBS. 
Animal procedures, tissue collection, CFUs and flow cytometry were 





1. Survival  
The efficacy of P4 treatment in combination with the antibiotic (Tazocin) was 
investigated during severe pneumonia (with secondary sepsis) caused by K. 
pneumoniae. Disease progression during this infection model is similar to 
that of Streptococcus pneumoniae so I used the same dosing schedule 
described by Bangert et al. (167). Doses of P4, IVIG and Tazocin were 
administered at 24 and 30 hours post infection, with P4 and Tazocin both 
being given intravenously and IVIG via intraperitoneal injection. Survival was 
monitored over a seven day period with surviving mice being culled at this 
point to confirm clearance of infection.   
The P4-IVIG + Tazocin group showed 70% survival at day seven compared 
with 20% for PBS and Tazocin groups and 30% for P4-IVIG and Tazocin-
IVIG groups (Figure 42). 
The mean survival time (p=0.04) Mean survival times for P4-IVIG + Tazocin 
were significantly longer compared to PBS treated mice (PBS mean survival 
= 78.3 hours, P4-IVIG + Tazocin mean survival time = 148.2 hours, p<0.05). 
Survival times for Tazocin (98.2 horus), Tazocin + IVIG (95.4 hours) and P4-




Figure 42 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model - Survival 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 




Figure 43. Double dose P4 therapy with antibiotics in K. pneumoniae infection model – Survival 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal instillation. 24 and 30 hours post infection mice were treated 
I.V. with 50 μl of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 mg/ml). Control mice received PBS injections 
of equal volume. Mice were monitored for signs of disease and culled when they reached ++ lethargic. Survival time in hours with mean and 
SEM. Analysed by one-way ANOVA test, p=0.0482 and Bonferroni’s post test * = p<0.05. 
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2. Bacterial Burden  
36 hours was chosen as the time point to assess bacterial burden as it is the 
last point at which there is 100% survival in all treatment groups.  
Both P4-IVIG + Tazocin treated mice (median CFUs = 0.0, IQR = 0 – 1.1 x 
104) and those treated with Tazocin alone (median CFUs = 2.4 x 103, IQR = 
3 x 102 – 8 x 103) showed significant reductions in blood CFUs compared 
with PBS treated mice (median CFUs = 1.6 x 105, IQR = 2.0 x 104 – 3.6 x 
106) (Figure 44- top).  
Both P4-IVIG + Tazocin treated mice (median CFUs = 3.333 x 105, IQR = 1.3 
x 105 – 7.5 x 105) and those treated with Tazocin alone (median CFUs = 4.0 
x 105, IQR = 3.8 x 104 – 3.8 x 106) also showed significant reductions in lung 
CFUs compared with PBS treated mice (median CFUs = 1.3 x 107, IQR = 7.3 





Figure 44. Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – Blood and Lung CFUs 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume.  
Top:Mice were monitored for signs of disease and culled at 36 hours post infection. 
Blood was collected for determination of CFUs. Analysed by Kruskal-Wallis test and 
Dunn’s multiple comparison test p=0.002, *** p<0.0001, * p<0.05. 
Bottom: Lung tissue was collected for determination of CFUs. Analysed by Kruskal-




3. Inflammatory Markers  
a) Plasma  
No significant differences were observed in CXCL1 (p=0.5), MIP-2 (p=0.2), or 
C5a (p=0.7) concentrations in plasma between the three groups. Plasma IL-
10 concentration was also measured but was below the level of detection of 




Figure 45. Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model  – Inflammatory markers in plasma (CXCL1 and MIP-2) 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 post infection. Blood was collected for 
determination of plasma cytokine concentrations. Plotted as median and IQR. 
Analysed by Kruskal-Wallis test and Dunn’s multiple comparison test -CXCL1 p=0.5, 
MIP-2 p=0.2  























































Figure 46 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model  – Inflammatory markers in plasma (C5a) 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. Twenty-four and 30 hours post infection mice were treated I.V. with 50 μl 
of P4 peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 post infection. Blood was collected for 
determination of plasma cytokine concentrations. Plotted as median and IQR. 
Analysed by Kruskal-Wallis test and Dunn’s multiple comparison p=0.7 
  
























































.No significant differences were seen between CXCL1 concentrations in the 
lungs (p=0.2) however there was a difference for MIP-2. The levels of MIP-2 
in the lungs were significantly higher in PBS treated mice compared to those 
treated with Tazocin (p=0.005), there was not significant difference between 
the levels in P4-IVIG + Tazocin and the other two groups (Figure 47).  
Tazocin treated mice had significantly higher levels of C5a (mean C5a = 373 
pg/ml) than those treated with PBS (mean C5a = 181 pg/ml p<0.05), they 
also had higher levels than P4-IVIG + Tazocin treated mice (mean C5a = 256 
pg/ml) but this difference was not statistically significant (Figure 48).  
IL-10 concentrations in the lung, levels were significantly lower (p<0.05) in 
both P4-IVIG + Tazocin (mean IL-10 = 854 pg/ml) and Tazocin (mean IL-10 = 
875 pg/ml) treated mice when compared to PBS (mean IL-10 = 2747 pg/ml) 






Figure 47 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – Inflammatory markers in Lung (CXCL1 and MIP-2) 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 post infection. Lung tissue was collected for 
determination of cytokine concentrations. Plotted as mean and SEM. Analysed by 




Figure 48 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – lung (C5a)  
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 and 48 hours post infection. Lung tissue was 
collected for determination of cytokine concentrations. Plotted as mean and SEM. 
Analysed by one-way ANOVA and Bonferroni post test p=0.03, * p<0.05. 
Figure 49 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – Lung IL-10 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 and 48 hours post infection. Lung tissue was 
collected for determination of cytokine concentrations. Plotted as mean and SEM. 
Analysed by one-way ANOVA and Bonferroni post test p=0.006 * p<0.05.  
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4. Cell populations and receptor expression  
a) Neutrophils  
Neutrophils were defined as CD45+, CD11b+ and Gr-1+ cells, neutrophil 
percentages were calculated as percentage of all CD45+ cells.  
A higher percentages of neutrophils were detected in the blood of P4-IVIG + 
Tazocin treated mice (mean = 44.13 %) at 36 hours post infection compared 
to Tazocin (mean - 27.55 %) and PBS  (mean = 30.33 %) treated mice (both 
p<0.005) (Figure 50, top panel). Percentages of neutrophils found in the lung 
tissue at 36 hours post infection showed no significant difference between 






Figure 50 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – percentage neutrophils in blood and lungs 
Mice n=5 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 post infection. 
Top: Blood was collected, red blood cells lysed and cells stained for subsequent 
analysis by flow cytometry, neutrophils were isolated as CD45+, Gr-1+ and CD11b+ 
cells. Plotted as mean and SEM. Analysed by one-way ANOVA and Bonferroni post 
test p=0.0008, ** p<0.005. 
Bottom: Lung tissue was collected, processed to a single cell suspension, red blood 
cells lysed and cells stained for subsequent analysis by flow cytometry, neutrophils 
were isolated as CD45+, Gr-1+ and CD11b+ cells. Plotted as median and IQR. 
Analysed by Kruskal-Wallis test p=0.2  
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b) Receptor expression  
The expression of cell surface receptors on neutrophils in the blood at 36 
hours post infection was measured. No difference was observed in the 
expression of CD64 (FcγRI) (p=0.8) or CD88  (p=0.7) although a statistically 
significant difference (p=0.02) was observed for CD32/16 (FcγRII/III); P4-
IVIG + Tazocin treated mice had higher levels of expression than Tazocin or 
PBS (p=0.05) treated mice (mean MFI for P4-IVIG + Tazocin = 17277, 
Tazocin = 13337 and PBS = 11581) (Figure 51 and Figure 52).   
Receptors CD11b (MAC-1, CR3) and CD35/21 (CR1/2) were also measured 





Figure 51 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – blood neutrophil receptor expression (FcγR) 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 hours post infection. Blood was collected, red 
blood cells lysed and cells stained for subsequent analysis by flow cytometry. 
Analysed by one-way ANOVA and Bonferroni post test –CD64 (FcγRI) p=0.8, 
CD32/16 (FcγRII/III) p=0.02, * p<0.05.  
































Figure 52 Double dose P4 therapy with antibiotics in K. pneumoniae infection 
model – blood neutrophil receptor expression C5aR 
Mice n=10 per group were infected with 1 x 105 CFU K. pneumoniae via intranasal 
instillation. 24 and 30 hours post infection mice were treated I.V. with 50 μl of P4 
peptide (2 mg/ml) and/or Tazocin (9 mg/mouse), I.P. with 100 μl of IVIG (100 
mg/ml). Control mice received PBS injections of equal volume. Mice were monitored 
for signs of disease and culled at 36 post infection. Blood was collected, red blood 
cells lysed and cells stained for subsequent analysis by flow cytometry. Analysed by 
one-way ANOVA and Bonferroni post test p=0.7. 
  
































D. Results Summary  
Treatment with a double dose of P4-IVIG + Tazocin led to higher percentage 
survival (70%) over 7 days than treatment with Tazocin alone (20%) and 
Tazocin+ IVIG (30%). Mean survival time was also significantly longer in P4-
IVIG + Tazocin treated mice compared with PBS treated mice (p<0.05).  
When CFUs were compared for P4-IVIG + Tazocin, Tazocin and PBS, 
treatment with both P4-IVIG + Tazocin and Tazocin alone led to a significant 
reduction in CFUs compared to control group. While decreases were similar 
in the lungs, the P4-IVIG + Tazocin treated group showed a far greater 
decrease in CFUs in the blood with 50 % of combination treated mice having 
no detectable CFUs in the blood at 36 hours.  
These three treatments showed no difference in plasma cytokine levels the 
levels however the level of C5a in the lungs were significantly higher for mice 
treated with Tazocin alone and the levels of IL-10 in the lung were highest for 
mice treated with PBS.  
The percentage of neutrophils found in the blood of P4-IVIG + Tazocin 
treated mice was significantly higher than for untreated controls and those 
treated with Tazocin alone. 
Expression of receptors on neutrophils from all groups showed similar levels 
of both CD64 and CD88 but differed in their expression of CD32/16. No 
differences were observed in receptor expression levels in the lung nor were 
there any difference in neutrophil percentage observed.  
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E.  Discussion  
1. Survival and bacterial burden 
Treatment with P4 peptide, IVIG and Tazocin lead to an increase in host 
survival (70%) when compared to both infected but non-treated control (20%) 
mice and those that received Tazocin (20%) or Tazocin in combination with 
IVIG (30%). Along with an increase in survival, mice treated with P4-IVIG + 
Tazocin in combination, saw a significant reduction in CFUs, this reduction in 
the lungs was similar to those treated with Tazocin alone but reductions in 
the blood were considerably higher with 50% of mice having no CFUs 
detectable at 36 hours post infection. This reduction in CFUs in blood is likely 
related to the increase in circulating neutrophils along with their higher level 
of CD32/16 expression.  
2. Inflammatory Markers 
a) Plasma 
No differences were observed in the levels of cytokine in the plasma of mice 
at 36 hours post infection. Whether differences would have be observed at 
an earlier time point, closer to the treatment times, is something that should 
be considered for further studies.  
b) Lungs  
Differences were observed in the levels of MIP-2, C5a and IL-10 in lung. The 
levels of CXCL1 in the lungs were not significantly different between 
treatment groups.  
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PBS treated mice had significantly higher levels of MIP-2 compared with 
Tazocin treated mice. This higher level of MIP-2 is likely due to a higher 
bacterial burden in the lung.  
Levels of C5a in the lung were highest for Tazocin treated mice, why this 
would be is unclear, expression of CD88 on lung neutrophils doesn’t suggest 
higher binding of C5a in the PBS or P4-IVIG treatment groups. 
The concentration of IL-10 in the lungs of PBS treated mice was significantly 
higher than in either Tazocin or P4-IVIG + Tazocin treated mice. K. 
pneumoniae capsule is known to induce IL-10 during pulmonary infection so 
the higher levels of bacteria in the lung of PBS treated mice could account for 
the higher levels of IL-10 (193). 
3. Cell populations 
a) Neutrophils percentages 
As seen with the pneumococcal models of invasive disease there was not a 
significant increase in lung neutrophils with intravenous P4 treatment (167).  
There was however a significantly higher percentage of neutrophils in the 
blood with P4-IVIG + Tazocin treatment compared with treatment with 
Tazocin or PBS. This higher proportion of neutrophils in the blood probably 
helped contribute to the reduction in CFUs seen in the blood.  
b) FcγR expression 
No differences were observed in the FcγR expression in the lung neutrophils. 
There was however a difference in the CD32/16 (FcγRII/III) expression in the 
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blood neutrophils, P4-IVIG + Tazocin treated mice had significantly higher 
levels of CD32/16 than PBS treated mice and higher expression than mice 
treated with Tazocin although this difference was not statistically significant. 
Higher levels of CD32/16 suggest more functionally mature cells and the 
potential for higher rates of phagocytosis, which is in line with the lower 
bacterial burden in the blood of these mice; over 50% of the mice had no 
detectable CFUs in the blood at 36 hours post infection. 
c) CD88   
No difference in CD88 expression was observed in either lung or blood 
neutrophils. This fits with the low levels of C5a found in the plasma and lung.  
4. Summary 
In summary treatment with P4-IVIG and Tazocin in combination was a 
successful treatment in the K. pneumoniae infection model where, unlike in 
the E. coli infection model, the combined therapy was superior to Tazocin-





Chapter IV. Ex vivo study of the 
effect of P4 peptide on neutrophils 
of patients with severe community 
acquired pneumonia  
 
 155 
A. Introduction  
1. Community Acquired Pneumoniae (CAP)  
Lower respiratory tract infections (LRTIs) and pneumonia are a major cause 
of mortality or morbidity across the globe; especially prevalent in low and 
middle-income countries, and the leading infectious cause of death in high-
income countries (194, 195). As well as high costs in terms of health, LTRIs 
are also a substantial economic burden on healthcare systems with 
European inpatient care costs for community acquired pneumonia (CAP) 
alone estimated at over €5 billion per year (196).   
Figure 53 Pathogen Detection among U.S. Adults with Community-Acquired 
Pneumonia Requiring Hospitalization, 2010–2012. 
From Jain et al. 2015 (37). 
Streptococcus pneumoniae is the most common cause of bacterial CAP 
requiring hospitalisation in recent reports from the US (Figure 53)(37).  
 
 156 
The etiology of CAP varies greatly between regions and age groups, and is 
also influenced greatly by socioeconomic factors. Risk factors for CAP in 
adult populations include: including age (>65 years <5 years), smoking, 
alcoholism, immunosuppressive conditions, and other chronic conditions 
such as COPD, cardiovascular disease, cerebrovascular disease, chronic 
liver or renal disease, diabetes mellitus and dementia (197).  
Severe CAP accounts for 6% of UK intensive care unit (ICU) admissions with 
mortality estimated at 35%, representing half of all CAP deaths. Overall 
hospital mortality sits at 50%, with an increasing incidence due to an aging 
population and rising antimicrobial resistance this is set to rise (198).  
Like sepsis, alternative treatments are need for the treatment of severe CAP.  
Previous work, which has shown P4 peptide to be an effective treatment for 
pneumococcal pneumoniae in murine models as well as its capacity to 
augment phagocytosis in both peripheral blood neutrophil and alveolar 
macrophages from differing populations of healthy volunteers(162, 167). This 
study, for the first time, is moving on from animal models and healthy human 
subjects to looks at P4 augmentation of phagocytic responses in peripheral 
blood neutrophils and alveolar macrophages from patients admitted to the 
intensive care unit (ICU) with a primary diagnosis of CAP.   
2. Opsonophagocytosis killing assay  
The primary endpoint of this study was the opsonophagocytosis killing assay 
(OPK). This assay was developed by the Centre for Disease Control and 
Protection CDC and was used to measure killing by phagocytic cells of 
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intravenous IgG (IVIG) opsonised pneumococci with and without P4 
stimulation (199). 
3. Clinical data 
In addition to the functional assays performed with patient cells, clinical data 
such as microbiology results, haematological and physiological measures 
were collected for each patient in order to see if there was any relationship 
between these measures and the cellular response to P4 peptide.  
4. Cell surface marker and serum cytokines  
Cell surface markers and serum cytokine levels were measured for each 
patient in order to see if there was any relationship between these measures 
and the cellular response to P4 peptide. 
5. P4 stimulation 
Ex vivo stimulation of peripheral blood neutrophils was performed to 
determine the effects of P4 peptide exposure on cell surface marker 
expression as well and the secretion of cytokines.  
 
 158 
B. Methods and Materials: 
1. Ethics Statement 
We obtained national research ethics approval (12/NW/0730) for this study. 
Informed consent was obtained from patients.  
2. Power calculations 
It was calculated that 20 samples (α=0.05, β=0.05) would be required to 
demonstrate a 25.5% increase in bacterial killing based on previously 
published data using human alveolar macrophages (162). 
3. Patients 
Patients were recruited between March 2013 – March 2014 from Aintree 
University Hospital and The Royal Liverpool University Hospital.    
Study inclusion criteria:  
I. Adults (>18years)  
II. Admitted to critical care with a diagnosis of severe community-
acquired pneumonia (CAP) in accordance with British Thoracic 
Society Guidelines (136).  
CAP was defined as: symptoms and signs consistent with an acute lower 
respiratory tract infection and new radiographic shadowing for which there 
was no other explanation. CAP was the primary reason for admission to ICU 




I. Hospital admission within past 14 days 
II. Pregnancy 
III. immunocompromise (e.g. HIV Infection or chemotherapy).  
4. Healthy Volunteers 
Healthy volunteers were recruited to serve as technical controls and 
consented for both bronchoalveolar lavage and blood sampling.  
Inclusion criteria:  
I. Adults aged 18-65 years.  Age chosen to minimise risk of 
bronchoscopy.    
II. Fluent spoken English.   
Exclusion criteria:  
I. Asthma or pre-existing lung disease requiring regular 
immunoregulatory treatment or having any recent ill health    
II. Cigarette smoking of greater than 10 pack years (20 cigarettes per 
day for 10 years)    
III. Chronic illness    
IV. Pregnancy    
5. Sampling 
All patients were recruited within 48 hours of admission to ICU and sampled 
within 7 days of recruitment. When research bronchoscopy was performed, 
blood samples were taken immediately prior to bronchoalveolar lavage. 
Venous blood samples were collected into 9 ml lithium heparin vacutainers. 
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Blood was transported from the hospital to the lab at room temperature in 
order to maintain optimal neutrophil viability. Research bronchoscopy was 
restricted to mechanically ventilated patients to avoid acute hypoxia in 
patients dependent on supportive oxygen therapy.  
Healthy human volunteer bronchoscopy was undertaken using published 
technique (200). This technique was used with modifications for intubated 
critical care patients. Briefly, patients were given adequate intravenous 
sedation (usually a combination of propofol and alfentanil), 100% oxygen and 
monitored closely for the duration of the procedure. Experienced critical care 
physicians undertook bronchoscopy via the endotracheal tube to enable 
anticipation and prompt management of any complications. Bronchoalveolar 
lavage samples were transported from the hospital to the lab on ice.  
6. Data collection 
Relevant patient data was collected prospectively using an a priori case 
report form. This data included basic demographic details, clinical markers of 
severity, microbiology data and patient outcome measures. 
7. Pneumococcal Stocks 
Frozen pneumococcal stocks were prepared for use in OPK assays. 
Serotype 2, strain D39 was streaked on to 5% blood agar plates and 
incubated 16-18 hours at 37°C in gas jars.  
The following day universal tubes containing 5 ml of BHI broth were 
inoculated with D39 from the agar plates and incubated statically for 16-18 
hours. The culture was then centrifuged at 3000 g for 10 minutes, the 
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supernatant discarded and the pellet resuspended in 1 ml of 20% serum BHI 
broth and diluted to give a 10ml culture at OD500 of 0.7. This was incubated 
until the culture reached an OD500 of 1.2-1.4 (max 6 hour growth). This 
culture was then aliquoted into 2 ml screw top tubes and frozen at -80°C. 
Between 24 and 48 hours after freezing aliquots were thawed and the CFU 
determined by Miles and Misra. 
8. Blood Cell Isolation 
Cells were isolated from blood by dextran sedimentation followed by 
centrifugation over a Histopaque 1077 (Sigma-Aldrich, UK).  
Blood was transferred from vacutainers (3 x 9 ml lithium heparin) into a 50 ml 
centrifuge tube containing 50 μl of heparin sodium salt (5 units/μl), (Sigma-
Aldrich, UK). The blood was then mixed 2:1 with 6% dextran (MW >500,000, 
Fisher, UK) and left for 20-30 minutes at room temperature for the red blood 
cells to sediment (see Figure 54, section A). 





After 20-30 minutes there should be two distinct phases; a dark red lower 
phase containing the red blood cells and a pale pink upper phase rich in 
leukocytes (see Figure 54 section B).  
The upper phase was collected and layered over 7 ml of Histopaque 1077 in 
a 15 ml centrifuge tube (see Figure 54, section C), 2 -3 tubes were needed 
per patient. Samples were then centrifuging at room temperature, 700g for 
30 minutes with no brake.The neutrophil (PMNs) and monocyte fractions 
were collected into separate 50 ml centrifuge and washed in Hank’s Buffered 
Salt Solution without Magnesium or Calcium (HBSS-/-), residual red blood 
cells were lysed with BD Pharm Lyse (BD Biosciences, USA) as per the 
manufacturer’s instructions. Cells were then counted with a haemocytometer 
and viability assessed by trypan blue exclusion.   
9. Alveolar Macrophage Isolation 
BAL samples were passed through a 100 μm cell strainer (BD Bioscience, 
Germany) before centrifuging at 400g, 4°C. BAL sample supernatants were 
aspirated and aliquoted for storage at -70°C. Cell pellets were washed and 
counted before resuspending in RPMI 1640 supplemented with 10% FBS, 
penicillin and streptomycin. Cells were seeded into flat bottom 96 well plates 
at a density of 1 x 105 alveolar macrophages per well. Cells were incubated 
at 37°C, 5% CO2 for two hours to allow alveolar macrophages to adhere 
before washing with PBS three times to remove non-adherent cells and 
antibiotic containing media.  
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10. Opsonisation of pneumococci 
Pneumococcal stocks were thawed, washed twice by centrifuging at 13,000 
rpm, discarding the supernatant and resuspending in +/+ HBSS, 5% FBS to 
give a final concentration of 5 x 104 CFU/ml (alveolar macrophage assays 
used 5 x 105 CFU/ml). IVIG (Gamunex-C, Grifols, Spain) was diluted 1:1 in  
+/+ HBSS, 5% FBS and then mixed with the diluted pneumococci 1:1 for 
opsonisation - 20 minutes, 37°C at 100rpm. The final concentration of IVIG in 
the assay is 1:16 which equates to 0.5 μg of protein. Un-opsonised controls 
used incubated as above in +/+ HBSS, 5% FBS at the same dilution.  
11. Opsonophagocytosis Assay - neutrophils 
Isolated neutrophils were seeded into 96 well U bottomed plates at a density 
of 5 × 104 neutrophils per well were incubated with 5 × 102 opsonised S. 
pneumoniae (20 μl per well of the pneumococci and IVIG mix from 
Opsonisation of pneumococci), 10 μl baby rabbit complement (Mast Group, 
UK), and P4 solution (10 μg/well) for 45 minutes at 37°C, 175rpm. CFU were 
determined following incubation by Miles and Misra. Wells not being treated 
with P4 received DEPC-treated water. Wells containing no neutrophils, non-
opsonised pneumococci and heat-inactivated complement were used as 
further controls. Killing index was calculated as 1 – dose well/OPA well (dose 
well - opsonised S. pneumoniae and complement, OPA well - phagocytes, 
opsonised S. pneumoniae and complement +/- P4 peptide)  
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12. Opsonophagocytosis Assay – alveolar macrophages  
Alveolar macrophages were seeded into 96 well flat bottomed plates (as 
detailed in Alveolar Macrophage Isolation) at a density of 1 x 105/well. After 
washing 5 × 103 opsonised S. pneumoniae (20 μl per well of the 
pneumococci and IVIG mix from Opsonisation of pneumococci) were added 
to wells along with 10 μl of 3-4 week baby rabbit complement and P4 solution 
(20 μg/well) for 45 minutes at 37°C, 100rpm. CFU were determined following 
incubation by Miles and Misra. Control wells received DEPC-treated water. 
Wells containing no macrophages, non-opsonised pneumococci and heat-
inactivated complement were used as further controls. Results of OPK 
assays were expressed as percentage killing index. 





 Dose well - opsonised S. pneumoniae and complement 
OPK well - phagocytes, opsonised S. pneumoniae and complement +/- P4 
peptide.   
13. P4 Stimulation 
Isolated neutrophils were resuspended in RPMI 1640 (Life Technologies, 
USA) supplemented with 10% FBS (Sigma-Aldrich, UK) and seeded into 96 
well plates at a density of 2 x 105 cells per well. P4 peptide was added to 
wells at a concentration of 20 μg/well. Control wells were made up to equal 
volume with DEPC-treated water.  Cells were incubated at 37°C, 30rpm for 
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45 minutes and 6 hours at which point cell were centrifuged at 300g, 
supernatants collected (stored at -70°C) and cell stained for cell surface 
markers following the procedure detailed below.  
14. Flow-cytometry  
Cell suspensions were stained for 20 minutes at 4°C (detailed in section 
II.B.4.b. The following antibodies were used: 
Ebioscience, UK 
 CD64 (FcγRI, 10.0-FITC) 
 CD32 (FcγRII, 6C4-APC) 
  CD16 (FcγRIII, CB16-PeCy7) 
 CD11b (CR3/Mac-1, CBRM1/5-PE) 
Biolegend, USA 
 CD88 (C5aR, S5/1-PeCy7) 
  CD35 (CR1, E11-FITC) 
 CD66b (CEACAM1, G10F5-PE) 
  CD181 (IL-8RA, 8F1/CXCR1-FITC) 
All cells were incubated with Trustain FcX Fc receptor blocking solution 
(Biolegend, USA) prior to staining with the exception those being stained with 
for CD64, CD32 and CD16. Isotype controls were used to exclude non 
specific binding. Acquisition was carried out using an Accuri C6 (BD 
Biosciences, USA) flow cytometer, and analysis was performed using FlowJo 




Serum was collected from each patient in 7.5 ml S-Monovette Z serum tubes 
(Sarstedt, Germany), tubes were centrifuged at 2000 g for 10 minutes and 
the serum aliquoted for storage at -70°C.  
IL-6, IL-8 and IL-10 levels were measured using Ready-SET-Go ELISAs 
(Ebioscience, UK) performed as per manufacturer’s instructions. Plates were 
read with a FLUOStar Omega plate reader and analysised with the MARS 
Data Analysis interface (BMG Labtech, Germany).   
16. Statistical Analysis 
Statistical analysis was performed with Prism 5 (Graphpad Software, USA), 




1. Healthy Controls  
Five healthy controls were recruited and OPK assays performed on their 
neutrophils throughout the study to help ensure all reagents were functioning 
as expected for the length of the study.  
The neutrophil OPK showed a statistically significant increase in killing index 
with P4 treatment (p=0.04), mean killing was 11% at baseline and increased 
to 28% with P4 treatment (Figure 55).  
The alveolar macrophage OPK showed an increase in mean killing from 24% 
at baseline to 52% with P4 treatment however was no statistically significant 
(p=0.1) (Figure 55).   
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Figure 55 OPKs from blood neutrophils and alveolar macrophages of healthy 
volunteers 
Killing index of untreated and P4 treated peripheral blood neutrophils (top) and 
alveolar macrophages (bottom) from health controls. Neutrophils p=0.04, alveolar 
macrophages p=0.1 paired t-test.     
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2. Patient Characteristics 
25 patients with community-acquired pneumonia (as defined by British 
Thoracic Society criteria [2]) were recruited into the study. All patients had 
severe pneumonia requiring admission to critical care for organ support and 
met the criteria for sepsis (see introduction). Table 16 depicts characteristics 
for 23 patients (two patients were excluded due to technical failure in testing) 
in our cohort.  
Samples were taken at a mean of 52 hours from admission (range 13-110 
hours) and processing began within one hour of sample collection. Fifteen 
(65%) patients were male, median age 54 (IQR 44-72) and median Acute 
Physiology and Chronic Health Evaluation II (APACHE II – disease severity 
score for ICU calculated within 24 hours of admission) score 15, IQR 11-24 
(Table 16). 
The was no relationship between APACHE II score and response to P4 
peptide in the OPK assay observed in our cohort although there was a trend 
towards a higher Sequential Organ Failure Assessment score (SOFA – 
scoring system used to track organ function in ICU, ranges from 0-24) in 
patients that did not respond to P4 in the OPK assay (mean SOFA score 
responders =5, mean SOFA score non responders = 8) (Figure 60).  
The 28 day survival for our cohort was 19/23 (17% mortality), of the four 
patients who died within 28 days, three died in the ICU. Ten patients had a 
causative organism identified (three blood culture positive). The most 
commonly isolated organism was Streptococcus pneumoniae (n=3, 1 blood 
culture, 2 urinary antigen)  (Table 16).  
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Major co-morbidities included: chronic obstructive pulmonary disease (8/23), 
ischaemic heart disease (6/23) and diabetes mellitus (4/23). 
Antimicrobial therapy for the majority of patients was a combination of either 
Piperacillin/Tazobactam (Tazocin) or benzylpenicillin combined with 
clarithromycin (Table 16).  
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Table 16 – Patient Characteristics – Orange = Responders, Blue = Non responders 
ID Age Microbiology APACHE II Antimicrobial therapy SOFA (Sampling) Co-morbidities 28 Day 
Survival 
A 83 E. coli 24 PIP/TAZ, CLAR 10 Asthma, IHD, AF YES 
B 30 S. milleri 11 PIP/TAZ, CLAR 7 Trisomy 21 YES 
C 42 Neg 8 CLAR, BPC 1 SLE, DVT YES 
D 37 H. influenza 8 Co-amoxiclav, CLAR 0 IVDU, Hepatitis C, DVT YES 
E 49 Neg 26 BPC, CLAR 6 COPD, IBD YES 
F 54 Legionella 15 CLAR 2 IBD NO 
G 73 Influenza A 24 PIP/TAZ, Tamiflu, CLAR 8 HTN, Breast cancer (treated) YES 
H 47 Neg 14 CLAR, BPC, Tamiflu 2 T2DM, IHD, CKD3 YES 
I 50 S. pneumoniae 18 Not completed 5 Alcoholism YES 
J 78 S. pneumoniae 14 CLAR, BPC 9 Nil significant YES 
K 61 Neg 9 PIP/TAZ, CLAR 3 COPD, RA NO 
L 72 Neg 22 Ciprofloxacin, PIP/TAZ 9 T2DM, mild dementia YES 
M 60 Neg 15 CLAR, BPC 2 COPD, AS YES 
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ID Age Microbiology APACHE II Antimicrobial therapy SOFA (Sampling) Co-morbidities 28 Day 
Survival 
N 39 Neg 13 CLAR, BPC 5 Asthma, T2DM, HTN YES 
O 31 Parainfluenza type 1 14 PIP/TAZ, Teicoplanin 4 Quadriplegic YES 
P 69 Neg 25 CLAR, BPC 12 IHD, Peripheral neuropathy YES 
Q 75 Neg 25 BPC, CLAR 9 AS, HTN, Stroke NO 
R 44 S. pneumoniae 8 PIP/TAZ, CLAR 3 COPD, IVDU, Asthma YES 
S 72 S. pneumoniae 24 BPC 10 Asthma, HTN Asbestosis, IHD YES 
T 48 Neg 25 CLAR, BPC 6 Paraplegic YES 
U 75 Neg 6 CLAR Vancomycin 10 COPD, HTN, Laryngeal cancer YES 
V 69 E. coli 13 PIP/TAZ, CLAR, 
Gentamicin 
14 COPD, ALD (Child C) NO 
W 49 Neg 2 CLAR, BPC 3 Sleep Apnoea, T2DM, HTN YES 
        
 
APACHE II - Acute physiology and chronic 
health evaluation II 




BPC – Benzylpenicillin  
CLAR – Clarithromycin  
PIP/TAZ –Tazocin   
Co-morbidities: 
AF – Atrial fibrillation 
ALD – Alcoholic liver disease  
AS – Aortic stenosis 
CKD – Chronic kidney disease 
COPD – Chronic obstructive pulmonary 
disease 
DVT – Deep vein thrombosis  
 
 
HTN – Hypertension 
IBD – Inflammatory bowel disease 
IHD – Ischaemic heart disease  
IVDU – Intravenous drug user 
RA – Rheumatoid arthritis   
SLE – Systemic lupus erythematosus 
T2DM – Type 2 Diabetes mellitus 
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3. Opsonophagocytosis Assays 
Blood neutrophil OPKs were completed in 23/25 patients (2 excluded due to 
technical failure). Fourteen (60%) samples responded to P4 peptide 
stimulation (fold increase > 1) (Figure 56).  
Treatment with P4 peptide compared to carrier control led to significantly 
improved ex vivo neutrophil phagocytic killing of pneumococci with a mean 





Figure 56 – Fold increase in killing index of peripheral blood neutrophils 
treated with P4 peptide 
Fold increase in killing index of P4 treated neutrophils when compared to untreated 
neutrophils for each of the 23 ICU patients. 56% (14/23) patients showed an 
increase in killing when treated with P4 peptide. Dotted line indicates a fold increase 
of 1, patients with a fold increase of 1 or less are considered non responders and 
are highlighted in blue (O-W), responders are highlighted in orange (A-N). Letters on 
the X axis correspond with the ID column in Table 16. 
  





























Figure 57 – Difference in killing index between P4 treated peripheral blood 
neutrophils and untreated neutrophils 
Difference in killing index between P4 treated and untreated peripheral blood 
neutrophils for each of the 23 ICU patients recruited (P4 killing index minus 
untreated killing index in each patient recovered neutrophil sample). 56% (14/23) 
patients showed an increase in killing when exposed to P4 peptide. Letter on the X 
axis correspond with the ID column in Table 16. Non responders and are highlighted 
in blue (O-W), responders are highlighted in orange (A-N). The cut-off for a 
response was set at a difference in killing index of 5 or more.  





























Patients were divided into responders and non responders using the cut off 
of an increase in killing index of 5% or more. Non responders had a mean 
baseline phagocytosis (OPK killing index with carrier control) of 30% this 
remained fairly static with P4 treatment killing index at 27%. The mean 
baseline phagocytosis for responders was 14%, with P4 treatment this 
increased significantly to 34% (p<0.0001 paired t test) (Figure 58). The 
difference between the baseline phagocytosis for responders and non 
responders was approaching significance (p=0.08, Mann Whitney). Figure 59 
shows the killing index before and after P4 treatment for each individual 




Figure 58 Killing index for peripheral blood neutrophils treated with P4 
peptide and untreated neutrophils 
Killing index of untreated and P4 treated peripheral blood neutrophils. Patients are 
divided into responders in orange (increase in killing index of 5 or more with P4 
treatment, n=13) and non responders in blue (increase in killing index of less than 5, 
n=10). Responders showed a significant increase in killing index with P4 treatment 




Figure 59 Killing index for peripheral blood and untreated neutrophils for 
individual patients neutrophils treated with P4 peptide 
Killing index of untreated and P4 treated peripheral blood neutrophils. Patients are 
divided into responders in orange (increase in killing index of 5 or more with P4 
treatment, n=13) and non responders in blue (increase in killing index of less than 5, 
n=10). When all 23 patients are taken into account treatment with P4 peptide 

































4. Patient Characteristics – Clinical Parameters  
The APACHE II and SOFA scores for patients and the predicted mortality 
associated with scores. Both the APACHE II and SOFA score are measures 
used in ICUs to assess disease severity. The APACHE II score is calculated 
at the time of admission (or within 24 hours) and is based on 12 physiological 
parameters as well as patient age. Based on the APACHE II score there was 
no significant difference in the disease severity for the two groups at 
admission (Figure 60, top panel).  
The SOFA score is calculated sequentially to monitor organ failure and is 
based on 6 scores assessing function in the respiratory, cardiovascular, 
hepatic, coagulation, renal and neurological systems. The non responder 
group showed a trend towards higher SOFA scores than responders which 





Figure 60 APACHE II and time of sampling SOFA scores 
APACHE II and SOFA scores for CAP patients recruited to study (n=14 responders 
- orange circles, n=9 non responders - blue squares). Patients are divided into 
responders and non responders depending on the response of their peripheral 
blood neutrophils to P4 peptide in the OPK. Top: The acute physiology and chronic 
health evaluation II score (APACHE II) was calculated within 24 hours of admission 
to ICU. There was no significant difference in APACHE II score between groups (t-
test). Bottom: The sequential organ failure assessment was calculated at the time of 
sampling. Non-responders had a higher SOFA score than responders (mean 
responders =5, mean non responders = 8) these values were approaching 












































The time from patient admission to sample collection was kept to a minimum 
but due to logistical reasons (such as admission at night or delays in 
acquiring consent) it was not always possible to acquire samples promptly. 
Sampling times ranged from 13 to 110 hours (mean 52 hours). The sampling 
time did not correlate with the patient SOFA score in our cohort (Figure 61, 
Top). The level of response to P4 peptide treatment also did not show a 






Figure 61 Effect of sampling time 
Effect of sampling time. Top: Patient SOFA score vs. time of sampling post 
admission – there was no relationship observed between the patient SOFA score 
and the time from admission to sampling in this cohort. Bottom: Difference in killing 
index vs. time of sampling post admission – there was no relationship observed 
between the difference in killing index and the time from admission to sampling in 
this cohort.  

















































5. Patient Characteristics – Neutrophils  
White blood cell (WBC) and neutrophil counts were performed by the hospital 
haematology service. When divided into responders and non-responders 
(Figure 62) there was no difference between the two groups in neutrophil or 
WBC count (p=0.1 and p=0.1 respectively).  
It was shown however that there was a weak (R squared value = 0.3) yet 
statistically significant (p=0.001) correlation between neutrophil count and the 
fold increase in killing with P4 peptide treatment in the OPK (Figure 63).  
It was noted that the patients with the highest neutrophil counts tended to 
have some of the lowest baseline phagocytosis values, although not 





Figure 62 Patient neutrophil and WBC count 
Neutrophil counts were provided for each patient by the hospital haematology 
laboratory. Top: Neutrophil count, bottom: white blood cell count (WBC) plotted as 
median and IQR. There was no statistical difference in neutrophil count between 
responders and non responders: neutrophil p=0.1, WBC p=0.1 Mann Whitney test. 
Patients marked in red had a neutrophil count below the detectable level for the 
automated counter – these patients have been recorded as having a neutrophil 




Figure 63 Neutrophil count vs fold increase in killing index 
Neutrophil count plotted against fold increase in neutrophil killing. Dotted red line 
indicates a fold increase of 1, pink band indicates the normal/health range for 
neutrophil count. R squared value = 0.3, p=0.0019. Patients marked in red had a 
neutrophil count below the detectable level for the automated counter – these 
patients have been recorded as having a neutrophil count of 1x109/L for statistical 
purposes. 
  































6. Patient Characteristics - Cytokines 
Serum cytokine levels for each patient were measured by ELISA. The 
detection threshold for the ELISA kits used was 2 pg/ml, where patients had 
cytokine levels lower than the threshold of detection they were recorded as 1 
pg/ml for statistical purposes. Patients were divided into responders and non 
responders for the analysis of serum cytokines.  
Responders had lower levels of IL-8 (median 11 pg/ml vs 88 pg/ml) and IL-10 
(median 1 pg/ml vs 8.62 pg/ml) than non responders (p=0.03 and p=0.01 





Figure 64. Patient serum cytokines – IL-8 and IL-10 
Serum cytokine levels for each of the 23 ICU patients recruited divided in respoders 
(orange circle) and non-responders (blue squares).  * = p<0.05 Mann Whitney test. 
Top- Serum IL-8 levels for individual patients, 5/23 patients had IL-8 levels below 
the detectable level (2 pg/ml) and were recorded as 1 pg/ml for statistical purposes. 
Median IL-8 level for responders was 11 pg/ml vs  88 pg/ml for non-responders 
(p=0.03, Mann Whitney test). Bottom- Serum IL-10 levels for individual patients, 
13/23 patients had IL-10 levels below the dtectable level (2 pg/ml) and were 
recorded as 1 pg/ml for statistical purposes. Median IL-10 level for responders was 
1 pg/ml (11/14 < 2 pg/ml) vs 8.62 pg/ml for non-responders (p=0.01, Mann Whitney 



































Figure 65 Patient serum cytokines IL-6 and INF-γ 
Serum cytokine levels for each of the 23 ICU patients recruited divided in respoders 
(orange circle) and non-responders (blue squares). Top: Serum IL-6 levels for 
individual patients – there was no statistical difference between patient levels for 
responders vs non responders (median 92 vs 108 pg/ml, p=0.8, Mann Whitney test). 
Bottom: Serum INF-γ levels for individual patients – there was no statistical 
difference between patient levels for responders vs non responders (median 1.0 vs 



















Figure 66 shows there was a weak yet significant negative correlation 
between serum IL-8 level and neutrophil count (R squared value = 0.2, 
p=0.02). IL-8 was also observed to have a positive relationship with the 
baseline level of phagocytosis, the higher the IL-8 the higher the baseline 
killing, although not significant for the cohort as whole (p=0.05) this 
relationship was significant when only the non responders were taken into 




Figure 66 Patient neutrophil count vs. serum IL-8 
Neutrophil count for each patient was plotted against their serum IL-8 level. R 
squared value = 0.2, p=0.02. Patients marked in red had a neutrophil count below 
the detectable level for the automated counter – these patients have been recorded 
as having a neutrophil count of 1x109/L for statistical purposes – both were non 
responders. 7/23 patients had IL-8 levels below the detectable level (2 pg/ml) and 




7. FcγR Expression  
The expression of CD64, CD32 and CD16 (FcγR I, II and III) on peripheral 
blood neutrophils was measured before as a baseline measurement and 
after a 45 minute stimulation with P4 peptide. There was no difference in 
baseline level of expression between responder and non responder group for 
any of the three receptors (Figure 67).  
CD32 expression on peripheral blood neutrophils of responders was shown 
to decrease by 46% from its baseline value when incubated with P4 peptide 
(p<0.01, Dunn’s multiple comparison following Friedmans test), there was no 
significant change in CD32 expression in the non responder group (Figure 
68).  
There was also no difference in observed in CD64 or CD16 after incubation 






Figure 67 Fc gamma receptor expression - CD64 (FcRI), CD32 (FcγRIIA/B)and 
CD16 (FcRIII) 
Fc gamma receptor expression on neutrophils from patients (n=9 responders, n=7 
non responders, n=7 patients lacked sufficient neutrophil numbers for testing or the 
sample was received too late for testing) using flow cytometry. There was no 
significant difference between the two groups in the expression level of CD64 p=0.4, 




































Figure 68 Effect of P4 on expression of CD32 on peripheral blood neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
CD32 (FcγRIIA/B) antibodies and expression levels determined by flow cytometry. 
Patients are divided into responders (orange, n=8) and non responders (blue, n=7). 
The responders showed a statistically significant drop from their baseline CD32 
expression after P4 treatment (responders p =0.03, non responders p=0.1, 
Friedman test, **= p<0.01 Dunn’s Multiple Comparison test). The responders saw a 
mean drop from baseline of 46%. Untreated neutrophils showed a drop from 
baseline of 27%.  
  
















Figure 69 Effect of P4 on expression of CD64 (FcγRI) and CD16 (FcγRIII) on 
peripheral blood neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
CD64 and CD16 antibodies and expression levels determined by flow cytometry. 
Patients are divided into responders (orange, n=8) and non responders (blue, n=7). 
There was no significant difference in expression after treatment.  






















8. Complement receptor expression 
No difference was observed in the expression of CD35 (CR1) or CD11b 
(CR3) between groups at baseline or after incubation with P4 peptide (Figure 





Figure 70 Complement receptor expression – CD35 and CD11b (CR1 and CR3) 
Complement receptor expression on neutrophils from patients (n=9 responders, n=7 
non responders, n=7 patients lacked sufficient neutrophil numbers for testing or the 
sample was received too late for testing) using flow cytometry. There was no 
significant difference between the two groups in the expression level of CD35 p=0.4 

























Figure 71 Effect of P4 on expression of CD35 and CD11b on peripheral blood 
neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
CD35 (CR1) and CD11b (CR3) antibodies and expression levels determined by flow 
cytometry. Patients are divided into responders (orange, n=8) and non responders 




CD66b is a marker of neutrophil activation, Figure 72 shows no difference 
was observed in the expression of CD66b between groups at baseline or 
after stimulation with P4 peptide as shown in Figure 73. Although it is of note 
that the non responder with the highest MFI (over 30,000) was the patient 
that had reduced killing in response to the P4 peptide which could suggest 
that there is of neutrophil activation after which P4 may have a negative 





Figure 72 CD66b (CEACAM8) expression 
CD66b (CEACAM8) expression on neutrophils from patients (n=9 responders, n=7 
non responders, n=7 patients lacked sufficient neutrophil numbers for testing or the 
sample was received too late for testing) using flow cytometry. There was no 
significant difference between the two groups in the expression level p=0.6 Mann 
Whitney test.  
Figure 73 Effect of P4 on expression of CD66b on peripheral blood neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
CD66b antibodies and expression levels determined by flow cytometry. Patients are 
divided into responders (orange, n=8) and non responders (blue, n=7). There was 














9. IL-8R expression 
Expression of the IL-8R on neutrophils isolated from the CAP patients was 
measured at baseline and after 45 minutes of stimulation with the P4 peptide.  
No difference was observed between responders and non responders in their 
baseline levels of IL-8R expression (Figure 77).  
After 45 minutes of treatment of with P4 peptide both groups saw a 
significant decline in the expression of the IL-8R on the cell surface. 
Responders saw a drop of 53% whilst non responders saw a drop of 33% 






Figure 74 IL-8 receptor (CXCR1) expression  
IL-8 receptor (CXCR1) expression on neutrophils from patients (n=9 responders, 
n=7 non responders, n=7 patients lacked sufficient neutrophil numbers for testing or 
the sample was received too late for testing) using flow cytometry. There was no 
significant difference between the two groups in the expression level. Mann Whitney 
test p=0.7. 
 
Figure 75 Effect of P4 peptide on IL-8R expression on peripheral blood 
neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
IL-8Rα (CD181/CXCR1) antibodies and expression levels determined by flow 
cytometry. Patients are divided into responders (orange, n=8) and non responders 
(blue, n=7). Both the responders and non responders showed a statistically 
significant drop from their baseline IL-8R expression after P4 treatment (responders 
p <0.0001, non responders p<0.001, Friedman test, ***= p<0.001, **= p<0.01 

























10. CD88 Expression 
Expression of the CD88  on neutrophils isolated from the CAP patients was 
measured at baseline and after 45 minutes of stimulation with the P4 peptide.  
No difference was observed between responders and non responders in their 
baseline levels of CD88 expression (Figure 76). After 45 minutes of 
treatment of with P4 peptide both groups saw a significant decline in the 
expression of the CD88 on the cell surface. Responders saw a drop of 36% 
whilst non responders saw a drop of 10% (p<0.01 and p<0.05 respectively) 




Figure 76 CD88  expression 
CD88 expression neutrophils from patients (n=9 responders, n=7 non responders, 
n=7 patients lacked sufficient neutrophil numbers for testing or the sample was 
received too late for testing) using flow cytometry. There was no significant 
difference between the two groups in the expression level. 
 
Figure 77 Effect of P4 peptide on CD88 expression on peripheral blood 
neutrophils 
Peripheral blood neutrophils were isolated from CAP patients before incubating for 
45 minutes in the presence of the P4 peptide. Cells were washed, stained with anti-
CD88  antibodies and expression levels determined by flow cytometry. Patients are 
divided into responders (orange, n=8) and non responders (blue, n=7). Both the 
responders and non responders showed a statistically significant drop from their 
baseline CD88 expression after P4 treatment (responders p <0.00, non responders 
p<0.01, Friedman test, **= p<0.01, *= p<0.05 Dunn’s Multiple Comparison test). The 
responders saw a mean drop from baseline of 36% whilst the non responders saw a 
drop of 10%. Untreated neutrophils showed a drop from baseline of 20% and an 


























11. Alveolar Macrophages 
Bronchoalveolar lavage (BAL) samples were collected from 3/23 patients in 
the study. Low sample numbers were due to the patients only receiving a 
research lavage if they needed one clinically. This meant lavages were often 
missed due to them being performed at short notice or overnight.  
Of the three BAL samples collected OPKs were performed successfully on 
two. The first sample received the bacterial dose (500 CFUs per well) was 
too low to show a difference between groups as the macrophages were very 
active, subsequent assays were performed with a ten fold higher dose.  
Figure 78 shows the results of these two OPKs. One patient showed an 
increase in killing index with P4 treatment from 72% to 93%. This patient was 
designated the letter S in the neutrophil studies and was a non responder. 
The other patient, who was designated G in the neutrophils and was a 
responder failed to show an improvement in killing in the alveolar 
macrophage OPK with a killing index of 86% at baseline and 89% with P4 




Figure 78 Alveolar macrophage OPK from CAP patients 
OPK using alveolar macrophages isolated from patient BAL samples. Patient S is 




D. Summary of results 
Neutrophils and alveolar macrophages from healthy controls showed 
increased phagocytosis after treatment with P4 ex vivo in line with what as 
been demonstrated in previous studies (162).   
Treatment of patient peripheral blood neutrophils with P4 peptide increases 
pneumococcal killing in 60% of the severe community-acquired pneumonia 
patients recruited to our study (p=0.002). A differential effect was observed 
with some patient neutrophils (40%) not showing a response to P4 peptide 
treatment in the OPK assay. However, the study was not sufficiently powered 
enough to fully decipher the reasons for these differences but there was a 
trend towards both a higher level of infection severity in non-responders 
(SOFA score p=0.0687) and a higher baseline level of opsonophagocytosis 
(p=0.0832) reducing the augmentative effect of P4.  
There was a weak yet significant correlation between total blood neutrophil 
count and the difference in pneumococcal killing with P4 treatment (R 
squared value = 0.3, p=0.0019). Patients’ serum cytokine data also showed a 
significantly higher level of both IL-8 and IL-10 in the serum of non 
responders (p=0·03 and 0·01 respectively) indicative of both neutrophil 
recruitment and anti-inflammatory effects.  
Cell surface marker data showed no significant difference in the baseline 
levels of any of the surface receptors measured. When cell surface markers 
were measured after treatment with P4 there was a statistically significant 
decrease from baseline levels in CD88 and IL-8R in both P4 peptide 




with P4 treatment but only in the responder group, non responders 





This is the first study to look at the ex vivo effects of the P4 peptide on 
human peripheral blood neutrophils during infection. The OPK assay was 
used as our end point for assessing efficacy of the peptide in our patient 
cohort.  
1. OPK 
A significant increase in pneumococcal killing index was seen for 60% of the 
patients studied. This is an encouraging result suggesting that P4 treatment 
could potentially be of benefit to patients suffering from severe CAP and 
sepsis.  
An important factor that must be taken into consideration however is that the 
OPK assay, being an ex vivo assay, may not give the whole picture as to 
which patients may or may not benefit from P4 treatment. The OPK assay 
doesn’t give a realistic representation of the conditions with the patients as 
the neutrophil numbers are adjusted to a standard number and the various 
cytokines, chemokines and other plasma components which could influence 
neutrophil function are removed. A whole blood phagocytosis assay may 
reveal differences between patients which aren’t seen in the neutrophil OKP 
used in this study. Another shortfall of this assay is that the protocol used for 
isolation of neutrophil precludes the isolation of the most immature 
neutrophils as their low density results in them being deposited in the PBMC 
fraction after density centrifugation (201). These immature neutrophils have 




more pro-inflammatory, hence would be an important population to study 
(202).   
2. Receptor expression 
a) CD88  and IL-8R 
This study looked at cell surface markers on neutrophils isolated from CAP 
patients and showed decreases in cell surface expression for both CD88 and 
IL-8R: two receptors important to neutrophil activation and chemotaxis, these 
changes occurred in both the responder and non responder group (203-205). 
Due to the short period of P4 stimulation (45 mins) that induced these 
reductions in receptor expression the most likely explanations are that the 
receptors were either internalised or cleaved from the cell surface. This could 
be confirmed by measuring levels of the receptor in the cell culture 
supernatant or with confocal imaging with fluorescently labelled receptors to 
capture receptor internalisation. Release of neutrophil elastase (NE) is 
mediated in part by the binding of C5a to CD88 and results in the cleavage of 
CD88 from other cells (127). It would be interesting to see if NE had been 
released into the supernatant in the presence of P4 and whether or not this is 
affected by the presence of FBS (as a potential source of C5a).   
This augmentation of receptor expression helps support the idea of the 
peptide having effects beyond just enhancing phagocytosis, such as 
augmenting timing and number of neutrophil infiltrating infection sites with P4 
treatment as shown in mouse models of pneumococcal infection treated with 




b) FcγR expression 
An interesting finding from this study was the effect of P4 on the expression 
of CD32 (FcγRII) on patient neutrophils, as one would not expect a decline in 
CD32 to result in increased phagocytosis . CD32B, one of the two isotypes of 
the CD32 molecules that has an inhibitory function, but it is not normally 
thought to be expressed by neutrophils though it can be induced under 
certain conditions (206). The ratio of CD32A:CD32B mRNA has been shown 
to be important in setting the threshold of activation in neutrophils (207). The 
antibodies used to detect CD32 in our study cannot distinguish between 
CD32A and CD32B so it is not possible to say if only one or both of these 
receptors is being affected by P4 treatment but is definitely a line of research 
worth pursuing in future studies.  
Expression levels of CD64 (FcγRI) and CD16 (FcγRIII) were not significantly 
different between responders and non responders, nor were any changes in 
expression observed after stimulation with P4 peptide. As CD64 has very low 
levels of expression in resting neutrophils it not be possible of P4 to induce 
further expression in CAP patients as it is already optimally expressed (177). 
Differences in the level of CD16 between patients may not have been evident 
because of the inability of the neutrophil separation method used to isolate 
the immature neutrophils which would have had lower levels od CD16 
expression (202).  
3. Inflammatory Markers 
Another finding, which could be significant when selecting patients who 




10 levels and response to treatment. Patients with high levels of IL-8 and IL-
10 were more likely to be non responders. This could be due to IL-8 priming 
neutrophils for phagocytosis and would in turn explain the higher baseline 
level of phagocytosis in non responders (208). Alternatively IL-10 has been 
shown to induce a refractory period in neutrophils during which activation in 
response to bacterial stimuli is blocked after an initial exposure to the stimuli 
in the presence of IL-10, which could explain why the non responders failed 
to show a improvement in phagocytosis with P4 peptide treatment (209). The 
interplay between IL-8, IL-10 and P4 treatment is worth investigating further 
to examine whether these cytokines are having an effect on the ability of P4 
to increase phagocytic activity. 
4. Effect of time 
If P4 therapy went through to clinical trials, its use is envisage as it being 
administered in a similar time frame to initial antibiotic treatment in sepsis i.e. 
within the first hours of sepsis being suspected. In this study samples were 
received from 13 to 110 hours after admission. No effect of time was 
observed in either the patient response to the drug or in severity of disease in 
patients. 
5. Alveolar macrophages 
The results of the alveolar macrophage OPK have too small a sample size to 
draw any definitive conclusions as to whether P4 can improve phagocytosis 
by macrophages in the lungs of CAP patients but they do highlight that it is 
possible that patients who don’t show a response to P4 in their blood 




6. Summary  
In summary this study has shown that treatment with P4 may have benefits 
for patients with severe CAP but as improvements in phagocytosis were not 
seen in all patients it would be important to investigate further what factors 
determine whether or not the neutrophils respond to treatment; patient 
plasma IL-8 and IL-10 levels may be worth investigating further which 
patients would benefit from P4. This study also showed that treatment with 
P4 did alter expression of CD32, CD88 and the IL-8R – it would be essential 
to investigate further what the effect of alter the cell surface expression of 










The working theory on the mechanism of P4 action is that it increases the 
levels of FcγR expression on phagocytic cells, which in turn leads to an 
increase in phagocytosis (167). This chapter looks at the effect of P4 on 
naïve mice in vivo and ex vivo.   
1. P4 treatment of naïve mice in vivo 
Mice were treat with P4 for 24 hours before being culled and their neutrophils 
analysed by flow cytometry to look at the effects of P4 on expression of 
CD88 , CD35/21 (CR1/2) and IL-8R.  
2. P4 treatment of naïve mouse neutrophils ex vivo 
Neutrophils isolated from naïve mouse bone marrow were treated with P4 in 





B. Method and Materials 
1. P4 treatment of naïve mice in vivo 
Female CD-1 mice aged 6-8 weeks were treatment with P4 peptide and then 
culled after 24 hours and blood collected for flow cytometry analysis.  
P4 peptide, dissolved in DEPC treated water, was administered via a 50 μl 
intravenous injection into the tail vein at a concentration final concentration 
per mouse of 1 μg, 10 μg and 100 μg. Control animals received an injection 
of equivalent volume of sterile PBS. 
2. P4 treatment of naïve mice ex vivo 
a) Tissue collection and neutrophil isolation 
Naïve mice were culled by cervical dislocation after which the femurs and 
tibias were collected and washed in 70% ethanol. The epiphyses were 
removed and the bone marrow flushed out of with a needle and syringe 
containing RPMI 1640 supplemented with 2 mM EDTA and 10% FBS.  
Cells were pelleted by centrifuging at 400 g, the supernatant removed and 
red blood cells lysed in 0.2% saline. Cells were pelleted again by centrifuging 
at 400 g, the supernatant removed and cells resuspended in 2 ml of RPMI 
1640 supplemented with 2% EDTA and 10% FBS.  
Histopaque 1119 and histopaque 1077 were layered over one another 
(histopaque 1077 on top), 2 ml of each, in a 15 ml centrifuge tube. The cell 
suspension was then layered on top of the histopaque and the tubes 




discarded and the neutrophil fraction collected. Neutrophils were counted 
with a haemocytometer and viability assessed via trypan blue exclusion.  
b) OPK and P4 treatment 
OPKs were performed as described in section IV.B.11. Neutrophils were 
resuspended in RPMI to give a concentration of 1.7 x 106 cells/ml. 
Neutrophils were seeded into 96 well plates, 180 μl per well. Wells were 
treated with either: P4 20 μl of 3 mg/ml dissolved in DEPC treated water or 
with DEPC treated water. Cells were incubated for 1 hour at 37 °C, 5% CO2.   
c) Receptor Expression  
Cells for receptor expression analysis were treated with P4 and DEPC 
treated water. The antibodies detailed in Table 17 with corresponding isotype 
controls were used for flow cytometry analysis of mouse tissue and 
leukocytes. Antibodies were used at a dilution of 1:250. Staining procedure is 
detailed in section II.B.4.b. Sample acquisition was performed on the FACS 
Calibur (BD Biosciences, USA) and analysis was performed with FlowJo 8.7 
(Tree Star, USA).    






101325 APC anti-mouse CD16/32 
139303 PE anti-mouse CD64 (FcγRI) 
123417 
APC/Cy7 anti-mouse CD21/CD35 
(CR2/CR1) 
149307 
PerCP/Cy5.5 anti-mouse CD182 
(CXCR2) 






1. P4 treatment of naïve mice in vivo  
Previous studies have shown the significant increases in the expression of 
FcγRs in naïve mice treated with P4 but no studies have looked at other 
receptors (167). CD88, CD35/21 (CR1/2) and CD182 (CXCR2) were chosen 
because of the evidence that complement may be an important factor in P4 
function; OPK assays without complement present fail to show an 
improvement in phagocytosis with P4 treatment (162). CD182 (CXCR2) was 
chosen because of the differences observed in the human ex vivo CAP study 
in IL-8R expression with P4 treatment.   
Figure 79 shows the expression of CD88 on neutrophils form mice treated in 
vivo for 24 hours with P4 peptide. The figure shows a dose dependent 
increase in CD88 expression with the highest expression found with 100 μg 
of P4 per mouse. The difference in expression was significantly different for 
control vs. 100 μg of P4 (p=0.005).  
Figure 80 shows the expression of CD35/21 on neutrophils form mice treated 
in vivo for 24 hours with P4 peptide. Levels of CD35/21 expression with P4 
treatment saw a 2 fold increase at a P4 concentration of 1 μg and a modest 
increase with 100 μg, these values were approaching significance (p=0.05).  
Figure 81 shows significantly higher expression of CD182 with 1 μg 
treatment with P4. Increases were not observed with 10 or 100 μg 






Figure 79 Effect of P4 on expression of CD88  on neutrophils of naïve mice 
Mice n=3-5 per group with injected intravenously with 50 μl of either  P4 or PBS. 
Mice were culled 24 hours after treatment and blood was collected, red blood cells 
were lysed and cells stained with anti-Gr-1, CD11b and CD88 antibodies for 
subsequent analysis by flow cytometry. Neutrophils were identified as GR-1+, 
CD11b+ cells. Plotted as mean and SEM, analysed by one-way ANOVA p=0.0074, 
**p<0.005 
Figure 80 Effect of P4 on expression of CD35/21 (CR1/2) on neutrophils of 
naïve mice 
Mice n=3-5 per group with injected intravenously with 50 μl of either  P4 or PBS. 
Mice were culled 24 hours after treatment and blood was collected, red blood cells 
were lysed and cells stained with anti-Gr-1, CD11b and CD35/21 antibodies for 
subsequent analysis by flow cytometry. Neutrophils were identified as GR-1+, 




Figure 81 Effect of P4 on expression of CD182 (CXCR2) on neutrophils of 
naïve mice  
Mice n=3-5 per group with injected intravenously with 50 μl of either  P4 or PBS. 
Mice were culled 24 hours after treatment and blood was collected, red blood cells 
were lysed and cells stained with anti-Gr-1, CD11b and CD182 antibodies for 
subsequent analysis by flow cytometry. Neutrophils were identified as GR-1+, 





2. P4 treatment of bone marrow neutrophils form naïve mice ex vivo 
As neutrophils are released in high numbers from the bone marrow during 
infection it was important to establish whether these neutrophils respond to 
P4 treatment. Figure 82 shows the difference in killing index with P4 treat of 
neutrophils isolated from the bone marrow of naïve mice. The neutrophils 
showed a significant increase in killing with P4 treatment (p=0.007). It was 
not possible to compare killing between blood and bone marrow neutrophils 
because the yields from neutrophils isolation from mouse blood is too low to 






Figure 82 Difference in killing index with P4 treatment - naïve bone marrow 
neutrophils  
Killing index of naïve bone marrow neutrophils in OPK assay with and without P4 
treatment. The neutrophils from the bone marrow of 7 mice were isolated and 





Figure 83 and Figure 84 show the effect of P4 treatment on expression of 
CD64 (FcγRI) and Cd32/16 (FcγRII/III) on neutrophils isolated from the bone 
marrow of naïve mice. Significant increases in CD64 were seen with P4 
treatment (p=0.03), a 2 fold increase in expression was observed. Increases 
in the expression of CD32/16 were only seen in 3/6 mice with P4 treatment 
(p=0.4). Why the neutrophils from some mice appeared to have a response 




Figure 83 Effect of P4 treatment on expression of CD64 (FcγRI) on naïve bone 
marrow neutrophils 
The bone marrow from 6 mice was collected and neutrophils isolated, neutrophils 
were treated with P4 or DEPC treated water for 1 hour before cells were stained 
with CD64 antibodies for subsequent analysis by flow cytometry. Analysed by paired 
t-test p=0.03. 
Figure 84 Effect of P4 treatment on expression of CD32/16 (FcγRII/III) on naïve 
bone marrow neutrophils 
The bone marrow from 6 mice was collected and neutrophils isolated, neutrophils 
were treated with P4 or DEPC treated water for 1 hour before cells were stained 
with CD32/16 antibodies for subsequent analysis by flow cytometry. Analysed by 





D. Results summary 
1. P4 treatment of naïve mice in vivo  
Treat of naïve mice in vivo with P4 resulted in significant increases 
expression of CD88  in a dose dependent manner. Increases in CD182 
(CXCR2) and CD35/21 (CR1/2) were also observed but unlike CD88 the 
highest expression was observed with 1 μg treatment and no dose 
dependent relationship was seen.   
2. P4 treatment of bone marrow neutrophils form naïve mice ex vivo 
OPKs with bone marrow neutrophils from naïve mice resulted in significant 
increases in killing index with P4 treatment.  
Ex vivo treatment with P4 of bone marrow neutrophils from naïve mice 
resulted in significant increases in CD64 after 1 hour. Differences in CD32/16 






E. Discussion  
1. P4 treatment of naïve mice in vivo  
Increased expression of receptors in naïve mice, other the CD32/16, has not 
previously been shown (167). The ability of P4 to modulate the expression of 
other receptors is an important finding with regards the mechanism of P4 
function. CD88 showed significant increases in expression after treatment 
with P4 and the fact that these changes in expression in detectable 24 hours 
after treatment with P4 peptide suggests that the effects of P4 on cells could 
be long lasting. It would be interesting to see how long the effects of P4 last 
in cells and how they change over time as this could effect the dosing 
schedules used in treatment. C5a is an extremely potent neutrophil 
chemoattractant so increased expression of the receptor could explain 
increases in neutrophils seen during infection with P4 treatment. Increases in 
CD182 could also contribute to increases in neutrophils. Binding of C5a to 
the CD88 has also been shown to play a role in regulation of CD16 
expression, so chances is CD16 expression could also be a result of 
changes in the expression CD88 (115). 
Significant increases in CD182 expression were also observed after P4 treat, 
however they did not display a dose dependent effect with the highest 
expression being in the group treated with 1 μg of P4. CD32/16 expression 
showed increases close to significance (p=0.0515) with P4 treatment but like 
the results seen for CD182 expression, levels were highest with 1 μg of P4. 
With this in mind, further studies should be performed looking at the dose 




2. P4 treatment of bone marrow neutrophils form naïve mice ex vivo 
The ability of neutrophils isolated from the bone marrow of naïve mice to 
respond to P4 in the OPK, which resulted in a significant increase in killing 
index with P4 treatment, is important as during infection large numbers of 
immature neutrophils are released from the bone marrow and in sepsis have 
been show to have reduced function compared with mature neutrophils 
normally found in circulation (202). This result should be followed up with 
studies of the effect of P4 peptide on neutrophil function during infection.  
The neutrophils showed significant increases in expression of CD64 with P4 
treatment. Baseline levels were very low in untreated cells, which helps 
support the theory that CD64 is not increased with P4 treatment during 
infection because it is already optimally expressed.  
Expression of CD32/16 was not significantly increased in all mice treated 
with P4, the mice with the lowest levels of CD32/16 without treatment with P4 
failed to show increases in expression whilst those with higher expression 
levels did show an increase. As an increase in expression this rapid is likely 
to be due to transport of intracellular stores of receptors to the cell surface it 
would be interesting to see if this mice had differed in the levels of stored 
receptors with the cell and hence were not capable of increasing their 





Chapter VI. Discussion 




A. Discussion  
1. Animal models 
The two animal models utilised in this study yielded very different results, 
which are briefly summarised in Table 18. The E. coli infection model was far 
more severe than the K. pneumoniae infection model, with control animals 
progressing to their humane endpoint within eight to ten hours of infection 
whilst controls in the K. pneumoniae model started showing signs of severe 
infection from 36 hours onwards and the mean survival time for controls was 
78 hours. 
The inflammatory response observed in the E.coli model was also markedly 
higher than in the K. pneumoniae model with CXCL1 levels in plasma almost 
300 fold higher and C5a levels 100 fold higher in E. coli infected mice. This 
excessive inflammatory response probably led to the very rapid decline in 
host survival in the E. coli infection model and therefore to see a protective 
effect of P4 treatment on mouse survival time would have needed some form 
of physiological support (such as fluid resuscitation, vasopressors and 
inotropic drugs), which is difficult to implement in animal models. Given the 
very rapid progression of infection it is likely that the high levels of 
inflammation was driven by high levels of LPS in E. coli infected mice. The 
infectious dose in the E. coli model was 100 fold higher than in the K. 
pneumoniae so it is possible that the initial inoculum contained substantial 
amounts of free LPS. In pilot experiments to set the dose for the E. coli 
model mice cleared the infection with doses of 106 CFUs/mouse and less. In 




concentration of LPS in the dose and if removal of this could improve survival 
in the model.   
The relatively slow progression of the K. pneumoniae infection allowed a 
larger window within which treatment could be administered i.e. treatment 
could be given before there was widespread inflammation in the model which 
could possibly counter the effects of P4 treatment. 
Another difference between the two models which may explain disparities in 
the results in the relation to Tazocin + IVIG treatment is the site of infection in 
relation to site of administration of IVIG: in the E. coli model the infectious 
dose and the IVIG were both given via intraperitoneal injection whilst in the 
K. pneumoniae model the infectious dose was given via the intranasal route 
and the IVIG via intraperitoneal injection. With the IVIG being administered 
directly into the initial site of infection in E. coli, improvements were seen in 
survival time of Tazocin + IVIG treated mice when compared to treatment 
with Tazocin alone. This could be because by administering the IVIG in close 
proximity to the infection site it was better able to slow the dissemination of 
infection from the peritoneum into the blood. These differences in survival 
were not observed between Tazocin and Tazocin + IVIG treated mice in the 
K. pneumoniae model where IVIG would have had to cross into the blood 
before circulating into the lungs. Which leads to the question as to whether 
Tazocin + IVIG treatment in E. coli infected mice would have still given a 
survival advantage over Tazocin alone if it had been administered through an 
alternative route such as intravenously, as it would be in humans. It was not 
possible to test this theory in the mice, as intravenous injection of IVIG (as in 




The K. pneumoniae infection model showed good efficacy of P4 treatment 
with P4-IVIG + Tazocin treatment resulting in 70% survival compared with 
20% survival in Tazocin treated groups and 30% survival in Tazocin + IVIG 
treated groups. This increase in survival was likely due to the lower numbers 
of CFUs in mice treated with P4 compared to control. Increases in CD32/16 
(FcγRII/III) expression in mice treated with P4 supports what has previously 
been published on the effects of P4 treatment on neutrophils and are likely to 
have resulted in in the lower numbers of CFUs (167).  
Whether P4 treatment provides a benefit in E. coli infection is not as clear 
cut; survival times and CFUs recovered from tissue were not significantly 
different for both P4-IVIG + Tazocin and Tazocin + IVIG treated mice. 
Cytokines and neutrophil receptor expression also did not differ significantly 
with P4-IVIG + Tazocin compared to mice treated with just Tazocin. To better 
establish whether P4 treatment is beneficial in E. coli infection, a less severe 
model, that more closely replicates the human progression to sepsis and 
allows longer survival times, such as a cecal ligation and puncture model 
could be used (210).  





Table 18 Comparison of E. coli and K. pneumoniae in vivo models 
 
 E. coli K. pneumoniae 
Infection Route Intraperitoneal Intranasal 
Inoculum per mouse 
(CFUs) 
107 105 
Dosing schedule post 
infection 
1 and 4 hours 24 and 30 hours 
Mean survival time of 
PBS control 
8 hours 78 hours 
Survival percentage 
in P4-IVIG + Tazocin 
55% at 24 hours 70% at 7 days 
Time pointed cull 7 hours 36 hours 
Plasma Cytokines – 
PBS control 
Very High CXCL1 




No detectable IL-10 
Plasma Cytokines – 
P4-IVIG + Tazocin 
Very High CXCL1 




No detectable IL-10 
Neutrophil 
percentage 
Elevated in Tazocin 
and P4-IVIG + Tazocin 
treated mice 
Elevated P4-IVIG + 
Tazocin treated mice 
only 
CD64 expression on 
neutrophils 
No difference No difference 
CD32/16 expression 
on neutrophils 
Elevated in Tazocin 
and P4-IVIG + Tazocin 
treated mice 
Elevated in P4-IVIG + 
Tazocin only 
CD88 expression on 
neutrophils 
Elevated in Tazocin 
and P4-IVIG + Tazocin 
treated mice 
No difference 




2. Ex vivo CAP study 
The ex vivo study on the effects of P4 on neutrophils from patients with 
severe CAP showed that treatment with P4 significantly increased 
phagocytosis, with 60% of the patients in the study showed an increase in 
killing. The patient sample size of this study limited further conclusions such 
as which patients would benefit from P4 treatment, although the difference in 
SOFA scores between responders and non responders suggested that P4 
efficacy declines as infection severity increases and hence the timing of 
treatment with P4 will likely have a major influence on treatment success. 
This relationship between infection severity and P4 efficacy was also 
demonstrated in the E. coli infection models, where it is likely that the rapid 
progression of the infection masked any benefits of P4 treatment.   
The group of patients that did not respond to P4 treatment in the OPK had 
significantly higher levels of IL-8 and IL-10 in their plasma than those that did 
show a significant response. Further work to establish if and how IL-8 and IL-
10 affect the ability of P4 to augment neutrophil function may help to advance 
understanding of P4’s mechanism of action. High levels of IL-8 may mean 
that the neutrophils are already optimally primed to respond to infection 
whereas high levels of IL-10 are known to attenuate neutrophil responses to 
stimuli such as LPS and this function may not be able to be recovered with 
P4 treatment (208, 209, 211).    
The results from the alveolar macrophage OPKs highlight that phagocytes 




treatment, so for some patients administration of P4 directly into the lungs 
may be beneficial.  
Changes to the expression of CD88 in both the animal models and the CAP 
patients and changes to IL-8R expression in the CAP patients suggest that 
there is more to the P4 mechanism than just increasing phagocytosis from 
augmentation of FcγRs. The fact that these changes were observed in naïve 
mice treated with P4 and not just during infection supports the idea that P4 
may be directly impacting on the expression of CD88 and IL-8Rs and that 
this is not just a by product of reduced infection severity. The implications of 
these changes in receptor expression on neutrophil responses to infection 
need further investigation.  
3. Future Work  
P4 has received funding through the MRC in the form of a Developmental 
Pathway Funding Scheme grant to further development of P4 as a 
therapeutic. As part of this grant P4 is currently undergoing toxicity testing 
(results due September 2016), which will hopefully lead to phase I and II 
clinical trials. With the possibility of P4 being administered to human subjects 
in mind, further work should be performed to better understand the 
mechanism of action of P4. The rapid nature of the up-regulation of FcγRs by 
P4 in vitro supports the idea that the receptors are being released from 
intracellular stores but how this is triggered remains elusive (162).  
Preliminary work utilising fluorescently labelled was performed to investigate 
the binding of P4 to cell surfaces and the possibility of the peptide being 




cytometry and confocal microscopy to investigate the fate of P4 during cell-
peptide interactions and showed that P4 binds to cell surfaces and 
suggested that around 13% of P4 that binds to cells is internalised. As part of 
this project PK/PD studies were also attempted, using HPLC to measure P4 
levels in plasma, these were unsuccessful with no P4 being detected in mice 
3 minutes (shortest time it was feasible to inject P4, anaesthetise mouse and 
collect blood) after injection. The fact that the peptide binds to cell surfaces 
and that some it is subsequently internalised may explain why PK/PD 
measurements were unsuccessful.  
Whether internalisation of P4 is necessary for P4 function is unknown. To 
better understand P4 function it would be important to know if P4 is entering 
cells and if so through what mechanism. P4 has an isoelectric point of 9, 
which makes it a cationic peptide. Cationic peptides can enter cells through a 
receptor independent manner as shown in Figure 85.  
Figure 85 Direct translocation of cationic peptide 
Examples of the proposed mechanisms for direct translocation. (A) Inverted micelle 





Each of these models is dependent on the net positive charge of the peptide 
disrupting the normal functioning of the cell membrane (212). The confocal 
images of fluorescent P4 in macrophages however show the peptide in 
spherical bodies within the cell, which suggests that direct translocation of 
the peptide may not be the route through which P4 enters cells and that a 
form of endocytosis may be more likely and could be confirmed with assays 
utilising endocytosis inhibitors. The fact that these confocal images do not 
show entry of peptide into all cells should be investigated further to confirm 
that uptake is definitely occurring and whether internalisation of P4 is 
important to P4 function or if binding of P4 to the cell surface is sufficient for 
the peptide to take its effect.  
The work performed so far with fluorescently labelled P4 (fP4) is preliminary 
and there are many more ways that fP4 could be utilised to answer questions 
about the mechanism of function of P4. One way it could be utilised is to 
investigate the fate of the peptide in vivo; using small animal imaging 
systems that can detect fluorescent compounds in live animals the peptide 
could be tracked within the mouse to answers questions such as do 
neutrophils treated with P4 show different patterns of migration within the 
mouse and how long these cells and the peptide itself persists.   
As severe infections occur disproportionately in those under 5 years, the 
elderly and immune-compromised patients it is important that studies 
investigate the efficacy of P4 in these populations are performed. Aging is 
known to result in a reduction in neutrophil function whilst maintaining normal 
neutrophil numbers, so a treatment, which could possibly enhance neutrophil 




Using P4 to treat fungal infections would also be of interest, severe fungal 
infections are increasing in prevalence and are an import cause of infection 
in ICUs (214). Given the difference in the way neutrophils process fungal 
hyphae compared with smaller pathogens it would be important to see if P4 
had an effect of the interaction between neutrophils and fungi (93). Patients 
with fungal infections are also often immune-compromised; HIV infected 
patients, those receiving chemotherapy and recipient of solid organ 
transplants are at particular risk of fungal infection and antifungal drugs often 
have high host toxicity so alternative treatment options would be of great 





A. Fluorescent P4 – Methods and Materials  
Fluorescently labelled P4 peptide was purchased from Peptide Synthetics 
(UK). The peptide was synthesised with an additional lysine residue labelled 
with TAMRA added to the C-terminal.   
1. Peptide binding 
Mouse neutrophils were isolated from bone marrow and treated with 
fluorescently labelled P4 as described in Chapter V.B.2. Treated cells were 
centrifuged at 300 g to pellet cells, the supernatant was discarded and the 
cells incubated for 5 mins with either PBS or trypsin. Cells were pelleted 
gain, the supernatant discarded and resuspended in RPMI before analysing 
by flow cytometry.   
2. Confocal imaging 
Confocal studies used J774 macrophages as strongly adherent cells were 
needed, when attempted with neutrophils the cells were too loosely adhered 
to allow proper focusing of the microscope.  
Macrophages were seeded into 35 mm glass bottom tissue culture dishes at 
a density of 106 cells per dish. After allowing to adhere for 2 hours cells were 
treated with fluorescently labelled P4 for 20 minutes. Cells were washed with 





1. Fluorescent P4 – flow cytometry 
What happens to P4 once it comes into contact with cells has not previously 
been studied. The following experiments were designed to explore the fate of 
P4 after contact with cells. Cells were washed with trypsin to remove surface 
bound peptide from cell before flow cytometry to establish whether P4 is 
entering cells or remains bound to cell surfaces.  
The top pane of Figure 86 shows fluorescence levels in neutrophils treated 
with fluorescently labelled P4, which have been washed in either PBS or 
trypsin. The bottom pane shows fluorescence levels in neutrophils treated 
with non fluorescent P4 and neutrophils treated with fluorescent P4 then 
washed in trypsin. Washing with trypsin led to a significant reduction in the 
fluorescence of neutrophils treated with fluorescent P4 (p=0.008). However 
the levels of fluorescence in trypsin treated neutrophils was still significantly 
higher than those treated with non fluorescent P4 (p=0.0313). Levels of 
fluorescence in trypsin washed cells were 13% of the levels of neutrophils 
washed in PBS. This suggests that some of the fluorescence could not be 





Figure 86 Binding of fluorescent P4 to naïve mouse bone marrow neutrophils 
The bone marrow from 6 mice was collected and neutrophils isolated, neutrophils 
were treated with fluorescent P4, normal P4 or DEPC treated water for 1 hour. Cells 
were then washed in either trypsin or PBS and the fluorescence of cells measured 
by flow cytometry. Top: Fluorescent P4 -PBS washed vs. trypsin washed. Bottom: 
Cells treated with non fluorescent P4 vs. fluorescent P4 washed in trypsin.  





2. Fluorescent P4 – confocal imaging  
Imaging of cells treated with fluorescent P4 was performed to further 
establish the fate of P4 when it comes into contact with cells.  
Figure 87 shows images of J774 macrophages treated for 20 mins with 
fluorescently labelled P4. Distinct spherical areas of fluorescent P4 (red) can 
be seen with the cells. 
 Figure 88 shows sequential Z-stacks at a distance of 1 μm between each 
image from A-D. The appearance of P4 (red) in sequential cuts through the 




Figure 87 Live confocal imaging of J774 macrophages treated with 
fluorescently labelled P4 
J774 macrophages were treated with P4 peptide for 20 mins, the cells were then 
washed with PBS before being imaged. P4 is shown in red.  
Figure 88 Live confocal imaging of J774 macrophages treated with 
fluorescently labelled P4 – Z stacks 
Live confocal image of J774 macrophage treated for 20 mins with fluorescently 







Bone marrow neutrophils from naïve mice bound P4 peptide as evidenced by 
increases in fluorescence in cells treated with fluorescently P4, 87% of this 
fluorescence was removed by treatment with trypsin but levels of 
fluorescence were still significantly higher than in cells treated with non-
fluorescent P4. This suggests the around 13% of the peptide may be 
internalised by the cells.   
Images of J774 macrophages suggest that the P4 peptide is internalised by 
cells within 20 mins of treatment with P4 peptide. It is noted however that not 
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